

JS011639930B2

(12) United States Patent

Kumar et al.

(10) Patent No.: US 11,639,930 B2

(45) **Date of Patent:** May 2, 2023

(54) ENHANCED CHEMILUMINESCENT ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF ANTIBODIES AGAINST BABESIA MICROTI

- (71) Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Silver Spring, MD (US); Yale University, New Haven, CT (US)
- (72) Inventors: Sanjai Kumar, Potomac, MD (US);
 Nitin Verma, Germantown, MD (US);
 Ankit Puri, Rockville, MD (US); Peter
 J. Krause, Old Saybrook, CT (US)
- (73) Assignees: The United States of America, as represented by the Secretary,

 Department of Health and Human

 Services, Silver Spring, MD (US); Yale

 University, New Haven, CT (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 321 days.

(21) Appl. No.: 16/761,034

(22) PCT Filed: Nov. 1, 2018

(86) PCT No.: **PCT/US2018/058723**

§ 371 (c)(1),

(2) Date: May 1, 2020

(87) PCT Pub. No.: WO2019/089936PCT Pub. Date: May 9, 2019

(65) Prior Publication Data

US 2021/0181190 A1 Jun. 17, 2021

Related U.S. Application Data

- (60) Provisional application No. 62/580,588, filed on Nov. 2, 2017.
- (51) Int. Cl. C07K 14/44 (2006.01) G01N 33/543 (2006.01) C12N 15/10 (2006.01) G01N 33/569 (2006.01)
- (52) U.S. CI.

 CPC G01N 33/54306 (2013.01); C07K 14/44

 (2013.01); C12N 15/1096 (2013.01); G01N

 33/56905 (2013.01); C07K 2319/00 (2013.01);

 G01N 2469/20 (2013.01)
- (58) Field of Classification Search
 CPC G01N 33/54306; G01N 2469/20; C07K
 14/44; C12N 15/1096
 See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

6,183,976	B1	2/2001	Reed et al.
6,214,971	B1	4/2001	Reed et al.
6,569,433			Reed et al.
8,178,310			Hoey et al.
8,283,124	B2	10/2012	Birkenmeyer et al.
2002/0169136	A1	11/2002	Reed et al.
2013/0244258			Erwin, III et al.
2015/0218657	A1	8/2015	Wang et al.

FOREIGN PATENT DOCUMENTS

EP	0834567		4/1998	
WO	WO 99/29869		6/1999	
WO	WO 00/60090		10/2000	
WO	WO 2013/059795		4/2013	
WO	WO-2013059795 A	41 *	4/2013	G01N 33/56905
WO	WO 2017/100598		6/2017	

OTHER PUBLICATIONS

Uniprot database entry with Database accession No. UNIPARC: UP1000274BDEB; with a date of Oct. 3, 2012 (Year: 2012).* Meredith et al. 2021 (Technologies for Detection of Babesia microti: Advances and Challenges; Pathogens 10: 1563). (Year: 2021).* Bloch et al., "A Prospective Evaluation of Chronic Babesia microti Infection in Seroreactive Blood Donors," *Transfusion*, vol. 56:1875-1882, 2016.

Cornillot et al., "A Targeted Immunomic Approach Identifies Diagnostic Antigens in the Human Pathogen *Babesia microti*," *Transfusion*, vol. 56:2085-2099, 2016.

Houghton et al., "Identification of *Babesia microti*-specific Immunodominant Epitopes and Development of a Peptide EIA for Detection of Antibodies in Serum," *Transfusion*, vol. 42: 1488-1496, 2002.

International Search Report and Written Opinion of PCT/US2018/058723, dated Mar. 20, 2019.

Levin et al., "Determination of *Babesia microti* Seroprevalence in Blood Donor Populations using an Investigational Enzyme Immunoassay," *Transfusion*, vol. 54:2237-2244, 2014.

Levin et al., "Serologic Screening of United States Blood Donors for *Babesia microti* using an Investigational Enzyme Immunoassay," *Transfusion*, vol. 56:1866-1874, 2016.

Silva et al., "Genome-wide Diversity and Gene Expression Profiling of *Babesia microti* Isolates Identify Polymorphic Genes that Mediate Host-Pathogen Interactions," *Sci. Rep.*, vol. 6:35284, 2016. UniPare Accession No. UPI000274BDEB, Oct. 3, 2012 (1 page). Vannier et al., "Babesiosis," *Infect. Dis. Clin. North Am.*, vol. 29:357-370, 2015.

* cited by examiner

Primary Examiner — Mary Maille Lyons (74) Attorney, Agent, or Firm — Klarquist Sparkman, LLP

(57) ABSTRACT

Identification of immunodominant *Babesia microti* antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting *B. microti*-specific antibodies in patient samples using the identified immunodominant antigens.

16 Claims, 4 Drawing Sheets

Specification includes a Sequence Listing.

Number of clones isolated




FIG. 2






FIG. 3





ENHANCED CHEMILUMINESCENT ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF ANTIBODIES AGAINST BABESIA MICROTI

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the U.S. National Stage of International Application No. PCT/US2018/058723, filed Nov. 1, ¹⁰ 2018, which was published in English under PCT Article 21(2), which claims priority to U.S. Provisional Application No. 62/580,588, filed Nov. 2, 2017, which is herein incorporated by reference in its entirety.

FIELD

This disclosure concerns identification of immunodominant *Babesia microti* antigens and their use in immunological detection assays.

BACKGROUND

Babesia microti, an intraerythrocytic protozoan parasite belonging to phylum Apicomplexan, is the causative agent 25 of human babesiosis. Ixodes scapularis, or the deer tick, is the primary vector that transmits this parasite to humans and its natural host, white-footed mice, during a blood meal. Babesiosis can also be transmitted by transfusion of blood and blood products collected from an infected donor (Mintz 30 et al., Transfusion 31:365, 1991). Human infection with Babesia microti is reported in Europe, Asia and Australia, but the highest prevalence of both tick- and transfusiontransmitted infections occurs in the United States with foci in the Northeast and upper Midwest. Since the first report of 35 babesiosis in the United States on Nantucket in 1969, the geographic range and incidence have been increasing. The Centers for Disease Control and Prevention (CDC) now classifies human babesiosis as an emerging and nationally notifiable disease. Most healthy adults infected by Babesia 40 are asymptomatic; however, the disease can be fatal in the elderly, immunocompromised patients regardless of age and asplenic individuals (Vannier et al., Infect Dis Clin North Am 29:357, 2015; Homer et al., Clin Microbiol Rev 13:451, 2000). Asymptomatic individuals infected with Babesia 45 represent a potential public health risk as there is currently no licensed donor screening assay for Babesia. Transfusiontransmitted babesiosis (TTB) is a major blood safety concern in United States; about 15 cases of TTB are reported annually with mortality rate as high as 20% (Kleinman and 50 Stassinopoulos, Transfusion 55:2983, 2015). Since 1979, when the first U.S. case of TTB was reported, more than 250 cases of TTB and 28 associated deaths have been documented in 22 states, although the actual numbers of cases are thought to be much higher (Herwaldt et al., Ann Intern Med 55 155:509, 2011; Kleinman and Stassinopoulos, Transfusion

The full genome sequence for *B. microti* became available in 2012 (Cornillot, E et al., *Nucleic Acids Res* 40:9102, 2012). However, there is a scarcity of well-characterized, 60 immunodominant *B. microti* antigens for applications in diagnostic assays and vaccine development. Among the currently available antibody-based assays, immunofluorescence assay (IFA) is the most sensitive and specific while the enzyme immunoassay (EIA)-based tests, which require antigenic recombinant proteins or synthetic peptides, have been less successful.

2

SUMMARY

Disclosed herein is the identification of three highly immunodominant *B. microti* antigens, referred to as *B. microti* serine rich antigen (BmSERA), *B. microti* maltese cross form related protein (BmMCFRP) and *B. microti* piroplasma β-strand (BmPiβS). These antigens were identified by genome-wide screening of a *B. microti* cDNA phage display library against a pool of human sera from babesiosis patients. Use of the immunodominant antigens in immunological assays for the detection of *B. microti*-specific antibodies is further disclosed.

Provided herein are methods for detecting antibodies specific for B. microti in a biological sample. In some 15 embodiments, the methods include providing at least one immunodominant B. microti antigenic polypeptide immobilized on a solid support; contacting the solid support with the biological sample under conditions sufficient to allow binding of any B. microti-specific antibodies present in the biological sample to the at least one B. microti antigenic polypeptide, thereby forming antigen-antibody complexes; and detecting the antigen-antibody complexes. In some examples, the at least one antigenic polypeptide is selected from a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 2 (BmSERA), a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 6 (BmPiβS). In specific non-limiting examples, the at least one antigenic polypeptide comprises BmSERA, BmMCFRP and BmPißS.

Also provided herein are kits, such as for the detection of *B. microti*-specific antibodies in a biological sample. In some embodiments, the kits include at least one immunodominant *B. microti* antigenic polypeptide. In some examples, the at least one antigenic polypeptide is selected from a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 2 (BmSERA), a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 6 (BmPiβS).

Further provided are fusion proteins and compositions that include a disclosed immunodominant *B. microti* antigenic polypeptide.

Isolated nucleic acid molecules and vectors encoding an immunodominant *B. microti* antigenic polypeptide are also provided herein.

The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic showing genome distribution of B. microti immunodominant antigens. The scale bar denotes the number of phage clones isolated for a specified gene following immunoscreening.

FIG. 2 is a schematic showing the domain architecture of *B. microti* antigens.

FIG. 3 shows SDS-PAGE analysis of His-tag purified, recombinant *B. microti* proteins BmSERA, BmMCFRP and BmPiβS. Proteins were separated on 4-12% SDS-PAGE gradient under reducing conditions and stained with Simply Blue Safestain. Lane M, molecular weight marker; Lane 1, BmSERA; Lane 2, BmMCFRP; Lane 3, BmPiβS.

FIG. **4** is a graph showing the results of a *Babesia microti* enzyme-linked immunosorbent assay (BmELISA) to determine the sensitivity of *B. microti* proteins.

SEQUENCE LISTING

The nucleic acid and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. The Sequence Listing is submitted as an ASCII text file, created on Apr. 28, 2020, 25.8 KB, which is incorporated by reference herein. In the accompanying sequence listing:

SEQ ID NO: 1 is the cDNA sequence encoding an antigenic *B. microti* serine rich antigen (BmSERA) polypeptide.

SEQ ID NO: 2 is the amino acid sequence of an antigenic BmSERA polypeptide.

SEQ ID NO: 3 is the cDNA sequence encoding an antigenic *B. microti* maltese cross form related protein (BmMCFRP) polypeptide.

SEQ ID NO: 4 is the amino acid sequence of an antigenic BmMCFRP polypeptide.

SEQ ID NO: 5 is the cDNA sequence encoding an antigenic *B. microti* piroplasma β -strand (BmPi β S) polypeptide.

SEQ ID NO: 6 is the amino acid sequence of an antigenic BmPiβS polypeptide.

SEQ ID NO: 7 is the nucleotide sequence encoding the full-length BmSERA protein, deposited under GenBank Accession No. XM_012794769.

SEQ ID NO: 8 is the amino acid sequence of the full-length BmSERA protein, deposited under GenBank Accession No. XP_012650223.

SEQ ID NO: 9 is the nucleotide sequence encoding the full-length BmPiβS protein, deposited under GenBank 40 Accession No. XM 012794124.

SEQ ID NO: 10 is the amino acid sequence of the full-length BmPiβS protein, deposited under GenBank Accession No. XP_012649578.

I. Abbreviations	DETAILED DESCRIPTION
BmELISA BmMCFRP	Babesia microti enzyme-linked immunosorbent assay B. microti maltese cross form related protein
BmPiβS	B. microti piroplasma β-strand
BmSERA	B. microti serine rich antigen
BSA	bovine serum albumin
cDNA	complementary DNA
DAPI	4',6-diamidino-2-phenylindole
EGF	epidermal growth factor
EIA	enzyme immunoassay
ECL-ELISA	enhanced chemiluminescence
	enzyme-linked immunosorbent assay
ELISA	enzyme-linked immunosorbent assays
HRP	horseradish peroxidase
IB	inclusion body
IFA	immunofluorescence assay
IPTG	isopropyl β-D-1-thiogalactopyranoside
RBC	red blood cell
RLU	relative light units
RT	room temperature
SNP	single nucleotide polymorphism
TM	transmembrane
TTB	transfusion-transmitted babesiosis

4

Terms and Methods

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms 15 are provided:

Antibody: An immunoglobulin molecule produced by B lymphoid cells with a specific amino acid sequence. Antibodies are evoked in humans or other animals by a specific antigen (immunogen). Antibodies are characterized by reacting specifically with the antigen in some demonstrable way, antibody and antigen each being defined in terms of the other. "Eliciting an antibody response" refers to the ability of an antigen or other molecule to induce the production of antibodies.

An antibody is a protein (or protein complex) that includes one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad of immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

The basic immunoglobulin (antibody) structural unit is generally a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" (about 50-70 kDa) chain. The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms "variable light chain" (V_L) and "variable heavy chain" (V_H) refer, respectively, to these light and heavy chains.

Antigen: A compound, composition, or substance that can stimulate the production of antibodies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous immunogens. Similarly, an "anti-genic" polypeptide is a polypeptide capable of inducing an immune response, such as the production of antibodies.

Antigen-specific: As used herein, an "antigen-specific" antibody is an antibody that was elicited (produced and/or activated) in response to a particular antigen. An "antigen-55 specific" antibody is capable of binding to the antigen, typically with high affinity.

Babesia microti: A protozoan parasite that infects erythrocytes and causes a benign to fatal disease called babesiosis. Transmission of *B. microti* between humans is most often attributable to a tick vector, but can also occur by transfusion of blood and blood products obtained from infected blood donors.

Babesia microti Serine Rich Antigen (BmSERA): A 946 amino acid protein with homology to serine-repeat antigen 4 (SERA). Bioinformatics analysis disclosed herein confirmed the localization of this protein as secreted/cell surface. A sequence homology search identified a homolog in

the Munich strain of B. microti where it reportedly has similar antigenic properties. BmSERA has 16 repeats of the sequence TNQP (residues 57-60 of SEQ ID NO: 2); the significance of this repeat sequence is not yet known. Similar four amino acid repeat sequences have been shown 5 in several of the *Plasmodium falciparum*: surface proteins (for example, circumsporozoite protein and merozoite surface protein). The predicted surface localization and the antigenic property of this protein confirm its immunogenicity and establish the molecule as having diagnostic potential. BmSERA mRNA and protein sequences are set forth herein as SEQ ID NOs: 7 and 8, respectively (see also GenBank Accession Nos. XM_012794769 and XP_012650223). A cDNA sequence encoding an antigenic BmSERA polypeptide is set forth herein as SEQ ID NO: 1. The amino acid sequence of the antigenic BmSERA polypeptide is set forth herein as SEQ ID NO: 2.

Babesia microti Maltese Cross Form Related Protein (BmMCFRP): A hypothetical protein of 177 amino acids 20 with homology to maltese cross form related protein (Gen-Bank Accession No. AB079857.1). This protein is thought to be involved in cytoskeleton remodeling, which provides evidence for its localization on the cell surface. A cDNA sequence encoding an antigenic BmMCFRP polypeptide is 25 set forth herein as SEQ ID NO: 3. The amino acid sequence of the antigenic BmMCFRP polypeptide is set forth herein as SEQ ID NO: 4.

Babesia microti Piroplasma 1-Strand domain (BmPiβS): A 271 amino acid protein belonging to the BMN2 family of 30 proteins. The presence of an amino terminal signal sequence makes it a secreted protein. The BmPiβS protein may play an important role in host-parasite dynamics. It is believed to be expressed on the cell-surface at the interface with the host immune system. BmPiβS mRNA and protein sequences are 35 set forth herein as SEQ ID NOs: 9 and 10, respectively (see also GenBank Accession Nos. XM_012794124 and XP_012649578). A cDNA sequence encoding an antigenic BmPiβS polypeptide is set forth herein as SEQ ID NO: 5. The amino acid sequence of the antigenic BmPiβS polypeptide is set forth herein as SEQ ID NO: 6.

Babesiosis: A malaria-like parasitic disease caused by infection with *Babesia*, a genus of Apicomplexa. Babesiosis typically occurs in the Northeastern and Midwestern United States and parts of Europe. Common symptoms of babesiosis include fever, hemolytic anemia, malaise and fatigue. Humans usually develop signs of illness 1 to 4 weeks after being bitten by a tick vector or 1 to 9 weeks after transfusion with contaminated RBCs.

Biological sample: A sample obtained from a subject 50 (such as a human or veterinary subject). Biological samples, include, for example, fluid, cell and/or tissue samples. In some embodiments herein, the biological sample is a fluid sample. Fluid sample include, but are not limited to, serum, blood, plasma, urine, feces, saliva, cerebral spinal fluid 55 (CSF) and bronchoalveolar lavage (BAL) fluid.

Conjugated: Refers to two molecules that are bonded together, for example by covalent bonds.

Contacting: Placement in direct physical association; includes both in solid and liquid form. In some examples, 60 "contacting" refers to incubating a molecule (such as an antigen) with a biological sample. As used herein, "contacting" is used interchangeably with "exposed."

Control: A reference standard, for example a positive control or negative control. A positive control is known to 65 provide a positive test result. A negative control is known to provide a negative test result. However, the reference stan-

6

dard can be a theoretical or computed result, for example a result obtained in a population.

Fluorescent protein: A protein that emits light of a certain wavelength when exposed to a particular wavelength of light. Fluorescent proteins include, but are not limited to, green fluorescent proteins, blue fluorescent proteins, cyan fluorescent proteins, yellow fluorescent proteins, orange fluorescent proteins, red fluorescent proteins and modified versions thereof.

Fluorophore: A chemical compound, which when excited by exposure to a particular wavelength of light, emits light (i.e., fluoresces), for example at a different wavelength.

Examples of fluorophores that may be used in the compositions and methods disclosed herein are provided in U.S. Pat. No. 5,866,366 to Nazarenko et al.: 4-acetamido-4'isothiocyanatostilbene-2,2'disulfonic acid, acridine and derivatives such as acridine and acridine isothiocyanate, 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic (EDANS), 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS), N-(4-anilino-1naphthyl)maleimide, anthranilamide, Brilliant Yellow, coumarin and derivatives such as coumarin, 7-amino-4methylcoumarin (AMC, Coumarin 120), 7-amino-4trifluoromethylcouluarin (Coumarin 151); cyanosine; 4',6diaminidino-2-phenylindole (DAPI); 5"-dibromopyrogallol-sulfonephthalein (Bromopyrogallol Red); 7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid; 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid; 5-[dimethylamino] naphthalene-1-sulfonyl chloride (DNS, dansyl chloride); 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL); 4-dimethylaminophenylazophenyl-4'-isothiocyanate

(DABITC); eosin and derivatives such as eosin and eosin isothiocyanate; erythrosin and derivatives such as erythrosin B and erythrosin isothiocyanate; ethidium; fluorescein and derivatives such as 5-carboxyfluorescein (FAM), 5-(4,6dichlorotriazin-2-yl)aminofluorescein (DTAF), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), fluorescein, fluorescein isothiocyanate (FITC), and QFTC (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferone; ortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; R-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives such as pyrene, pyrene butyrate and succinimidvl 1-pyrene butyrate: Reactive Red 4 (Cibacron®, Brilliant Red 3B-A); rhodamine and derivatives such as 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride, rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101 and sulfonyl chloride derivative of sulforhodamine 101 (Texas Red): N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid and terbium

Other suitable fluorophores include thiol-reactive europium chelates which emit at approximately 617 nm (Heyduk and Heyduk, *Analyt. Biochem.* 248:216-27, 1997; *J. Biol. Chem.* 274:3315-22, 1999).

chelate derivatives.

Other suitable fluorophores include GFP, LissamineTM, diethylaminocoumarin, fluorescein chlorotriazinyl, naphthofluorescein, 4,7-dichlororhodamine and xanthene (as described in U.S. Pat. No. 5,800,996 to Le et al.) and derivatives thereof. Other fluorophores known to those skilled in the art may also be used.

Fusion protein: A protein containing amino acid sequence from at least two different (heterologous) proteins or peptides. Fusion proteins can be generated, for example, by expression of a nucleic acid sequence engineered from nucleic acid sequences encoding at least a portion of two 5 different (heterologous) proteins. To create a fusion protein, the nucleic acid sequences must be in the same reading frame and contain no internal stop codons. Fusion proteins, particularly short fusion proteins, can also be generated by chemical synthesis.

Heterologous: A heterologous protein or polypeptide refers to a protein or polypeptide derived from a different source or species.

Isolated: An "isolated" biological component (such as a nucleic acid molecule, protein, antibody or cell) has been 15 substantially separated or purified away from other biological components in the cell, blood or tissue of the organism, or the organism itself, in which the component naturally occurs, such as other chromosomal and extra-chromosomal DNA and RNA, proteins and cells. Nucleic acid molecules 20 and proteins (including antibodies) that have been "isolated" include those purified by standard purification methods. The term also embraces nucleic acid molecules, proteins and antibodies prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acid molecules, 25 proteins and antibodies.

Label: A compound or composition conjugated directly or indirectly to another molecule, such as an antibody, protein or microparticle/microsphere, to facilitate detection of that molecule. As used herein, "label" is used interchangeably 30 with "detectable label." Specific, non-limiting examples of labels include fluorescent tags, enzymes, and radioactive isotopes. "Labeling" refers to the act of linking a label to a molecule of interest, for example linking to the molecule of interest a component that subsequently binds a detectable 35 label or linking a detectable label itself to the molecule of interest, or both. Various methods of labeling polypeptides and other molecules are known in the art and may be used. Examples of detectable labels for polypeptides include, but are not limited to, the following: radioisotopes or radio-nucleotides (such as ³⁵S, ¹¹C, ¹³N, ¹⁵O, ¹⁸F, ¹⁹F, ⁹⁹mTc, ¹³¹I, ³H, ¹⁴C, ¹⁵N, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In and ¹²⁵I), fluorescent labels (such as fluorescent proteins, fluorophores, fluorescein isothiocyanate (FITC), rhodamine, lanthanide phosphors), enzymatic labels (such as horseradish peroxidase, beta- 45 galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, chromophores (such as horseradish peroxidase or alkaline phosphatase), biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (such as a leucine zipper pair sequences, 50 binding sites for secondary antibodies, metal binding domains, epitope tags), or magnetic agents, such as gadolinium chelates.

Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first 55 nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two proteincoding regions, in the same reading frame.

Polypeptide: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either 65 the L-optical isomer or the D-optical isomer can be used. The terms "polypeptide" or "protein" as used herein are

8

intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced. The term "residue" or "amino acid residue" includes reference to an amino acid that is incorporated into a protein, polypeptide, or peptide.

A conservative substitution in a polypeptide is substitution of one amino acid residue in a protein sequence for a different amino acid residue having similar biochemical properties. Typically, conservative substitutions have little to no impact on the activity of a resulting polypeptide. For example, a B. microti protein including one or more conservative substitutions (for example no more than 2, 5, 10, 20, 30, 40, or 50 substitutions) retains the structure and function of the wild-type protein. A polypeptide can be produced to contain one or more conservative substitutions by manipulating the nucleotide sequence that encodes that polypeptide using, for example, standard procedures such as site-directed mutagenesis or PCR. In one example, such variants can be readily selected by testing antibody crossreactivity or its ability to induce an immune response. Examples of conservative substitutions are shown below.

Original Residue	Conservative Substitutions
Ala	Ser
Arg	Lys
Asn	Gln, His
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
His	Asn; Gln
Ile	Leu, Val
Leu	Ile; Val
Lys	Arg; Gln; Glu
Met	Leu; Ile
Phe	Met; Leu; Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp; Phe
Val	Ile; Leu

Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

The substitutions which in general are expected to produce the greatest changes in protein properties will be non-conservative, for instance changes in which (a) a hydrophilic residue, for example, seryl or threonyl, is substituted for (or by) a hydrophobic residue, for example, leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, for example, lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, for example, glutamyl or aspartyl; or (d) a residue having a bulky side chain, for example, phenylalanine, is substituted for (or by) one not having a side chain, for example, glycine.

Purified: The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified protein/polypeptide preparation is one in which the polypeptide or protein is more enriched than the polypeptide or protein is in its natural environment within a cell. In one embodiment, a preparation is purified such that

the protein or polypeptide represents at least 50% of the total polypeptide or protein content of the preparation. Substantial purification denotes purification from other proteins or cellular components. A substantially purified protein is at least 60%, 70%, 80%, 90%, 95% or 98% pure. Thus, in one 5 specific, non-limiting example, a substantially purified protein is 90% free of other proteins or cellular components.

Secondary antibody: An antibody that specifically recognizes the Fc region of a particular isotype of antibody (for example specifically recognizes human IgG or human IgM). 10 Secondary antibodies for use with the methods and kits disclosed herein include, but are not limited to, anti-human IgG and anti-human IgM. In some embodiments herein, the secondary antibody is conjugated to a detectable label, such as a fluorophore, enzyme or radioisotope, to facilitate detec- 15 tion of immune complexes to which the secondary antibody

Sequence identity/similarity: The identity/similarity between two or more nucleic acid sequences, or two or more amino acid sequences, is expressed in terms of the identity 20 or similarity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are. Sequence similarity can be measured in terms of percentage similarity (which takes into account conservative amino acid substi- 25 tutions); the higher the percentage, the more similar the sequences are. Homologs or orthologs of nucleic acid or amino acid sequences possess a relatively high degree of sequence identity/similarity when aligned using standard

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. USA 85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res. 16:10881-90, 1988; Huang et al. Computer Appls. in the Biosciences 8, 155-65, 1992; and Pearson et al., Meth. Mol. Bio. 24:307-31, 1994. Altschul et al., J. 40 Mol. Biol. 215:403-10, 1990, presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403-10, 1990) is available 45 from several sources, including the National Center for Biological Information (NCBI, National Library of Medicine, Building 38A, Room 8N805, Bethesda, Md. 20894) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. 50 Additional information can be found at the NCBI web site.

BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. If the two compared sequences share homology, then the designated output file will present those regions of homol- 55 ogy as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.

Serum: The fluid portion of the blood that separates out from clotted blood. Serum contains many proteins, includ- 60 ing antibodies, but does not contain clotting factors.

Solid support: Any inert material having a rigid or semirigid surface. In the context of the present disclosure, the solid support is capable of binding directly or indirectly to a polypeptide or an antibody (such as a secondary antibody). 65 The solid support can have any shape, form or size (for example, plate, sheet, tube, stick or particle). In some

10

embodiments herein, the solid support is a multi-well plate (also referred to as a microtiter or microwell plate), membrane, glass, metal, bead, microsphere, test tube, test stick, test strip, porous matrix or resin. In some examples, the solid support includes polystyrene, polyethylene or polypropyl-

Subject: Living multi-cellular vertebrate organisms, a category that includes human and non-human mammals.

Synthetic: Produced by artificial means in a laboratory, for example a synthetic nucleic acid or polypeptide can be chemically synthesized in a laboratory.

Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. "Comprising A or B" means including A, or B, or A and B. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Introduction

The present disclosure describes the use of a B. microti 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. 35 bacteriophage display library to identify immunodominant B. microti antigens. The immunodominant antigens were evaluated in immunodetection assays, including an enhanced chemiluminescence enzyme-linked immunosorbent assay (ECL-ELISA), to detect B. microti-specific antibodies in serum samples from babesiosis patients. Phage display is a selection technique in which a library of peptide or protein variants is expressed on the outside of a phage virion, while the genetic material encoding each variant resides in the phage genome. Thus, each variant protein sequence is physically linked to the DNA it encodes (Smith, Science 228:1315, 1985). The B. microti phage display library was constructed from parasite complementary DNA (cDNA) and subjected to affinity selection on a pooled panel of babesiosis patient sera. The B. microti cDNA library was cloned into the gene encoding viral surface protein gIIIp such that the B. microti antigens were expressed at the N-terminus of gIIIp and displayed on the surface of M13 phage. The M13 phage display system has been extensively validated for the efficient expression and display of protein domains (Smith, Science 228:1315, 1985).

The study disclosed herein identified more than 50 immunodominant B. microti antigens, the majority of which had no known function. Bioinformatics analyses were performed to characterize the potential biochemical and cellular functions of each antigen. These antigens were ranked based on their reactivity to the pooled babesiosis patient sera and 19 of the top-ranking antigens were tested in ELISA for their potential as diagnostic antigens. After extensive performance testing and validation, the three most immuno-reactive antigens were identified, which are referred to herein as Babesia microti SErine Repeat Antigen (BmSERA), Babesia microti Maltese Cross Form Related Protein

, ,

(BmMCFRP) and *Babesia microti* Piroplasma β-Strand domain (BmPiβS). When all three antigens were used in combination, ECL-BmELISA recognized 27/28 (96%) of babesiosis patient sera and 0 of 15 (0%) sera samples from individuals who had no known history of babesiosis. Thus, disclosed herein are immuno-based detection methods that utilize the *B. microti* antigens to identify *B. microti*-specific antibodies in biological samples. Such methods can be used, for example, to diagnose a subject as having a *B. microti* infection or to screen donor blood for exposure to *B. microti*.

11

Overview of Several Embodiments

Disclosed herein is the identification of three highly immunodominant *B. microti* antigens, referred to as *B. microti* serine rich antigen (BmSERA), *B. microti* maltese cross form related protein (BmMCFRP) and *B. microti* piroplasma β-strand (BmPiβS). These antigens were identified by genome-wide screening of a *B. microti* cDNA phage display library against a pool of human sera from babesiosis patients. Use of the immunodominant antigens in immunological assays for the detection *B. microti*-specific antibodies is further disclosed.

Provided herein is a method for detecting antibodies 25 specific for *B. microti* in a biological sample. In some embodiments, the method includes providing at least one immunodominant *B. microti* antigenic polypeptide immobilized on a solid support; contacting the solid support with the biological sample under conditions sufficient to allow binding of any *B. microti*-specific antibodies present in the biological sample to the at least one *B. microti* antigenic polypeptide, thereby forming antigen-antibody complexes; and detecting the antigen-antibody complexes.

Also provided herein is a method of diagnosing a subject as having a *B. microti* infection. In some embodiments, the method includes providing at least one immunodominant *B. microti* antigenic polypeptide immobilized on a solid support; contacting the solid support with a biological sample obtained from the subject under conditions sufficient to allow binding of any *B. microti*-specific antibodies present in the biological sample to the at least one *B. microti* antigenic polypeptide, thereby forming antigen-antibody complexes; and diagnosing the subject as having a *B. microti* 45 infection by detecting the antigen-antibody complexes.

In some embodiments of the disclosed methods, the at least one antigenic polypeptide is selected from a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, 50 at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 (BmSERA), a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% 55 identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPiβS).

In some examples of the disclosed methods, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to 65 SEQ ID NO: 2 (BmSERA) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%,

at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:

4 (BmMCFRP).

In other examples, the at least one an

In other examples, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 (BmSERA) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPiβS).

In other examples, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPiβS).

In yet other examples, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 (BmSERA), a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPi β S).

In one non-limiting example, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 2, a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 4 and a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 6.

In another non-limiting example, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 2, a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 4 and a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 6

In yet another non-limiting example, the at least one antigenic polypeptide includes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 6.

In some examples, the at least one antigenic polypeptide is selected from a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 6.

In some embodiments, detecting the antigen-antibody complexes includes contacting the antigen-antibody complexes with a secondary antibody conjugated to a label; and detecting binding of the secondary antibody to the antigenantibody complexes. In some examples, the label includes an enzyme and detecting binding of the secondary antibody to the antigen-antibody complexes comprises detecting

activity of the enzyme. In specific examples, the enzyme is horseradish peroxidase (HRP). In some examples, the label includes a fluorescent protein and detecting binding of the secondary antibody to the antigen-antibody complexes comprises detecting fluorescence. A suitable label for use in an 5 immunoassay, and a corresponding detection method, can be selected by one skill in the art.

In some examples, the secondary antibody comprises anti-human IgG, anti-human IgM, or both.

In some examples, the biological sample comprises blood 10 or a component thereof, such as serum.

In some embodiments of the method of diagnosing a subject as having a *B. microti* infection, the method further includes treating the *B. microti* infection in the subject. In some examples, treatment of the infection includes administration of one or more of atovaquone, azithromycin, clindamycin and quinine.

Further provided are kits, such as for the detection of *B. microti*-specific antibodies in a biological sample, or the diagnosis of a subject as having a *B. microti* infection. In 20 some embodiments, the kits include at least one immunodominant *B. microti* antigenic polypeptide.

In some embodiments of the disclosed kits, the at least one antigenic polypeptide is selected from a polypeptide comprising an amino acid sequence at least 90%, at least 25 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 (BmSERA), a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, 30 at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% 35 identical to SEQ ID NO: 6 (BmPiβS).

In some examples of the disclosed kits, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 40 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 (BmSERA) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4 45 (BmMCFRP).

In other examples, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% 50 or at least 99% identical to SEQ ID NO: 2 (BmSERA) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPiβS).

In other examples, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4 (BmMCFRP) and 60 a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPi β S).

In yet other examples, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least

14

93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 (BmSERA), a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4 (BmMCFRP) and a polypeptide comprising an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 (BmPi β S).

In one non-limiting example, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 2, a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 4 and a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO:

In another non-limiting example, the at least one antigenic polypeptide includes a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 2, a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 4 and a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO:

In yet another non-limiting example, the at least one antigenic polypeptide includes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 6.

In some examples of the disclosed kits, the at least one antigenic polypeptide is selected from a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 6.

In some embodiments of the disclosed kits, the at least one antigenic polypeptide is immobilized on a solid support. In some examples, the solid support comprises a multi-well plate.

Further provided are fusion proteins that include a Babesia microti antigenic polypeptide fused to a heterologous peptide. In some embodiments, the heterologous peptide comprises an affinity tag, an epitope tag, a fluorescent protein, an enzyme or a carrier protein. In particular examples, the enzyme is HRP, chloramphenicol acetyl transferase (CAT), β-galactosidase, luciferase or alkaline phosphatase (AP). In particular examples, the affinity tag is chitin binding protein, maltose binding protein, glutathione-Stransferase or poly-His (such as hexa-His). In particular examples, the epitope tag is V5, c-myc, HA or FLAG. In particular examples, the fluorescent tag is GFP or another well-known fluorescent protein. In particular examples, the 55 carrier protein is keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or ovalbumin (OVA). In some embodiments, the amino acid sequence of the B. microti antigenic polypeptide consists of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. In other embodiments, the B. microti antigenic polypeptide is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4.

Also provided are compositions that include a *Babesia microti* antigenic polypeptide immobilized on a solid support. In some embodiments, the solid support includes a multi-well plate, a membrane, a bead, a microsphere, a test

tube, a test stick or a test strip. In some embodiments, the amino acid sequence of the B. microti antigenic polypeptide consists of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. In other embodiments, the B. microti antigenic polypeptide is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4.

Further provided are isolated nucleic acid molecules encoding a Babesia microti antigenic polypeptide. In some embodiments, the amino acid sequence of the B. microti antigenic polypeptide consists of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. In some examples, the nucleotide sequence of the isolated nucleic acid molecule consists of 15 SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5. In other examples, the nucleotide sequence of the isolated nucleic acid molecule is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least identical to SEQ ID NO: 3. Vectors that includes an isolated nucleic acid molecule disclosed herein operably linked to a heterologous promoter are also provided.

Also provide is an isolated polypeptide, wherein the amino acid sequence of the polypeptide is at least 80%, at 25 least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4. In some examples, the amino acid sequence of the polypeptide comprises SEQ ID NO: 4. Isolated nucleic acid molecules encoding the isolated polypeptides are further provided.

Further provided is an isolated nucleic acid molecule, comprising a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 35% 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 3. In some examples, the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 3.

Detection of Babesia microti Antibodies in Patient Samples and Donor Blood

Serological methods of detecting B. microti-specific antibodies in a biological sample, such as a serum or blood 45 sample, are disclosed herein. These methods use the immunodominant B. microti antigenic polypeptides disclosed herein. Detection assays based on binding of an antigen to an antibody are well known in the art and include, for example, ELISA, microsphere immunoassay (MIA), immu- 50 nofluorescence assay (IFA), Western blot, fluorescence activated cell sorting (FACS), radioimmunoassay (RIA) and immunohistochemistry (IHC). As is well known to one of skill in the art, in some cases the detection assay further includes the step of contacting an antigen-antibody complex 55 with a detection reagent, such as a labeled secondary antibody (e.g., an anti-isotype antibody, such as an anti-IgG or anti-IgM antibody), or in the case of a sandwich ELISA, a second antibody that recognizes the same antigen as the first antibody and is labeled for detection. Secondary antibodies 60 can also be conjugated to magnetic beads to allow for magnetic sorting. The B. microti antigenic polypeptides disclosed herein can be used with a variety of immuno-based detection assays for the detection of B. microti-specific antibodies in patient samples or donor blood, and/or for the 65 diagnosis of B. microti infection. Several exemplary immuno-based detection assays are described below.

16

A. Indirect ELISA

In one embodiment, disclosed herein is an enhanced chemiluminescent ELISA (ECL-ELISA), which is an indirect ELISA. An indirect ELISA is performed by immobilizing antigen, such as an immunodominant B. microti antigenic polypeptide, on a solid support, for example the wells of a microtiter plate. A biological sample, such as a diluted serum or blood sample, is added to the immobilized antigen such that any antigen-specific antibodies present in the biological sample will bind to the immobilized antigen. A labelled secondary antibody, such as an anti-IgM or an anti-IgM antibody, is added. The label on the secondary antibody can be, for example, an enzyme or a fluorophore. The detectable label is then measured (activity of the enzyme following addition of an appropriate substrate, or fluorescence) to detect the presence of antigen-specific antibodies that were present in the serum or blood sample.

The ECL-ELISA disclosed herein is described in Example 95%, at least 96%, at least 97%, at least 98% or at least 99% 20 1. In the ECL-ELISA, one or all three of the disclosed immunodominant B. microti antigenic polypeptide(s) is/are immobilized on a multi-well plate. After washing and blocking steps, diluted test serum was added to the wells and incubated. After washing, diluted HRP-conjugated antihuman IgG and IgM antibody was added and incubated. The plates were then washed and SuperSignal™ ELISA Pico Chemiluminescent Substrate (Thermo Fisher Scientific, MA) was added for 5 minutes and relative light units (RLUs) were measured.

B. IgM or IgG Antibody Capture ELISAs

The immune response following a B. microti infection includes the production of IgM and IgG antibodies. IgM antibody capture (MAC) or IgG antibody capture (GAC) ELISAs can be used to detect the level of IgM or IgG (respectively) in serum samples of patients suspected of having a B. microti infection or to screen donor blood for exposure to B. microti. In these assays, anti-human IgM or anti-human IgG serves as a capture antibody and is coated 40 onto an appropriate assay plate, such as a multi-well plate. After blocking of the plate, such as with nonfat dry milk, diluted human sera are reacted with the anti-human IgM or IgG. In the context of the present disclosure, one or more immunodominant B. microti antigenic polypeptides are added to the plates. A B. microti-specific antibody conjugated directly or indirectly to detectable label (for example, an enzyme or fluorophore) is then reacted with the immobilized antigen. The detectable label is then measured to detect the presence of B. microti-specific antibodies that were present in the serum or blood sample. Serial dilutions of positive sera can be evaluated. The maximum dilution that exhibits positive signal is the titer for the serum.

C. Sandwich ELISA

A sandwich ELISA to detect the presence of B. microtispecific antibodies can be carried out by coating a microtiter plate with a B. microti-specific antibody, blocking the plates to prevent non-specific binding to the plate surface, and adding one or more immunodominant B. microti antigenic polypeptides to allow binding of the antigenic polypeptides to the B. microti-specific antibody. After washing, samples (such as diluted serum or blood samples) are added to allow binding of any antibodies present in the sample to the immobilized antigenic polypeptides. IgM or IgG antibodies that were present in the sample are then detected using a labelled secondary antibody, such as anti-human IgG or anti-human IgM conjugated to a detectable label (such as an enzyme or fluorophore). The presence of B. microti-specific

antibodies is detected by measuring the detectable label (for example, by measuring fluorescence, optical density or colorimetric absorbance).

17

D. Microsphere Immunoassay (MIA)

Microsphere immunoassays are becoming increasingly 5 popular for laboratory diagnosis of many diseases (Earley et al., *Cytometry* 50:239-242, 2002; Kellar et al., *Cytometry* 45:27-36, 2001). The technology involves the detection and analysis of a reaction (such as an antibody or other ligand) attached to microspheres or beads. The detecting instrument 10 is a simplified flow cytometer, and lasers simultaneously identify the microsphere sets and measure the fluorescence associated with the reaction. The speed at which these tests can be performed and the ability to multiplex make this methodology particularly useful.

A MIA can be used to detect the presence of B. microtispecific antibodies in a sample. In some embodiments, microsphere beads are coated with a B. microti-specific antibody and contacted with immunodominant B. microti antigenic polypeptides (as disclosed herein) such that the 20 antigenic polypeptides bind to the microsphere-bound B. microti-specific antibodies. The microsphere immune complexes are mixed with a serum sample such that antibodies in the sample that are specifically reactive with an immunodominant B. microti antigenic polypeptide bind the anti- 25 genic polypeptides bound (indirectly) to the microsphere. The bead-bound immune complexes are allowed to react with fluorescent-dye labeled anti-species antibody (such as PE-labeled anti-human IgM or anti-human IgG), and are measured using a microsphere reader (such as a Luminex 30 instrument). In an alternative embodiment, microsphere beads are coated directly with the immunodominant B. microti antigenic polypeptides and antigenic polypeptidebound microspheres are contacted with the serum samples.

E. Lateral Flow Assay (LFA)

Lateral flow immunoassays are another method by which antigen-specific antibodies can be detected in biological samples. These assays are generally very rapid and enable point of care testing. LFA is performed over a strip, different parts of which are assembled on a plastic backing. These 40 parts are sample application pad, conjugate pad, nitrocellulose membrane and adsorption pad. Nitrocellulose membrane is further divided into test and control lines. Pre-immobilized reagents at different parts of the strip become active upon flow of liquid sample. LFA combines the unique 45 advantages of biorecognition probes and chromatography.

Several designs have been developed for lateral flow assays. Generally, LFAs include a porous support strip (such as a strip of cellulose) with a number of separate regions spaced horizontally along the support. The solid support 50 need not be identical in all regions of a strip. Typically, the first region is a sample pad where a biological fluid is applied to flow laterally through the support to the remaining regions. The second region generally contains a labeling moiety that can be bound to the analyte of interest (such as 55 an antibody or protein) in the sample if present. Downstream of the labeling region is a capture or "test" region where the labeled analyte (for example, antibody or peptide) is retained in the strip. It is in this test region where detection is generally performed. In addition to the test region, the strip 60 may contain a control region either in the same flow path as that of the test region, or in a parallel path on the strip. There may also be a reservoir downstream of the various regions to absorb the sample that has traversed the test strip.

LFAs can be direct assays, forming sandwiches in pro- 65 portion to the level of analyte present, or may be competition assays where analyte in the sample diminishes the amount of

18

label detected in the detection zone. In direct sandwich assays, for example, the sample may be labeled by colored particles that are coupled to affinity reagents such as secondary antibodies that bind *B. microti*-specific antibodies present in the sample, forming complexes which are then carried to the test region for capture by an additional reagent. The detectable label in the test region will be directly proportional to the level of analyte (such as an antigen-specific antibody) in the sample.

In competitive assays, the labeling region may contain labeled reagents, for example, that are already coupled to the target analyte (e.g. antibody) or an analog thereof, and the analytes in the sample compete with this labeled material for capture by the capture reagent in the test region. In this case, the detectable label in the test region will be inversely proportional to the quantity of analyte in the sample itself.

Simple visual detection is the most common means of reading an LFA, however, there are commercially available lateral flow readers that can quantitate the detectable label in the test region.

The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.

EXAMPLES

Example 1: Materials and Methods

This example describes the experimental procedures used for the studies described in Example 2.

B. microti Parasites

B. microti (Franca) Reichenow Peabody strain (Ruebush, J Parasitol 65:430, 1979) was obtained from the American
Type Culture Collection (ATCC; Manassas, Va.). Female DBA/2NCr mice were injected with B. microti parasites and the parasite infected red blood cells (RBCs) were isolated at 15-20% parasitemia.

Construction of B. microti cDNA Phage Library

B. microti parasites were harvested by lysing the infected RBCs with sarkosyl buffer (10 mM Tris-HCl (pH 7.5), 10 mM EDTA, 10 mM NaCl, 0.5% Sarkosyl). The B. microti RNA was prepared using TRIZOLTM reagent (Life Technologies, Grand Island, N.Y.), followed by chloroform extraction and precipitation performed with isopropyl alcohol and ethanol. Complimentary DNA (cDNA) encompassing the entire open reading frames was prepared from the B. microti RNA using SMART® cDNA library construction kit (Clontech laboratories, Inc., CA) following the manufacturer's instructions. Briefly, the first strand cDNA was synthesized from the B. microti RNA using a modified oligo (dT) primer and SMART IV oligonucleotide primers. The second-strand cDNA was made using Long Distance (LD) PCR conditions. The synthesized double-stranded cDNA (~10 μg) was subjected to controlled fragmentation using sonication (Model FB120; Sonic Dismembrator, Thermo Fisher Scientific, MA) to generate small (50-300 bp) and large (300-1000 bp) cDNA library fragments, which were separated by agarose gel electrophoresis. These cDNA fragments were dephosphorylated and polished to obtain blunt ended fragments to be ligated into Sma I (CCC^GGG) digested M13-derived phage vector. The ligation products were transformed into Escherichia coli TG1 cells (Agilent technologies, MD) and selected for recombinants (tet') on tetracycline plates. Transformed cells were cultured at 37° C. with shaking at 250 rpm in 100 ml of 2×YT broth containing 5 μg/ml tetracycline for approximately 16 hours. The recom-

binant lysogenic phages displaying the fusion protein domain were recovered from the supernatant and the phage titer was determined. The cDNA inserts were expressed as NH₂-terminal fusion to the gIIIp surface protein of the M13 phage. Both small (50-300 bp) and large fragment (300-51000 bp) *B. microti* libraries yielded 10⁶ independent clones as established by limiting dilution of the transformed bacterial cells. Forty-eight clones were picked from each library and PCR amplified using phage specific primers and sequenced to determine the random distribution and diversity of the *B. microti* genome libraries.

Immunoscreening Via Panning

A pool of seven babesiosis patient sera (anti-B. microti IFA titer>1:500) were used for panning of the B. microti 15 library. To minimize non-specific reactivity, pooled babesiosis serum was incubated with ultraviolet-killed M13K07 phage-coated petri dishes. For the affinity panning of the phage library, 96-well maxisorp microwell plates (Immulon 4 HBX, Thermo Scientific, Rochester) were coated over- 20 night at 4° C. with 1 μg of goat anti-human IgG Fcγ antibodies in phosphate-buffered saline (PBS), pH 7.4. After three washings with PBST (20 mM PBS (pH 7.4) containing 0.1% Tween 20), 5% bovine serum albumin (BSA fraction V, Sigma-Aldrich) in PBST was added to the wells to block 25 the unoccupied reactive sites. Pre-adsorbed babesiosis patient sera was added to the wells and incubated for 1 hour at room temperature (RT). Wells were washed three times with PBST, and 10⁶ phages from the B. microti library were added for 1 hour at RT. Non-adherent phages were removed 30 by 9 washes with PBST followed by 3 washes with PBS. The adherent phages were eluted by the addition of 0.1 N Glycine-HCl (pH 2.2), 100 µl per well for 10 minutes at 37° C. The eluate was immediately neutralized by the addition of 2 M Tris (pH unadjusted). The eluate was simultaneously 35 titrated and amplified for the next round of panning in log phase (OD_{600 nm}~0.8) E. coli TG1 cells. For the phage amplification, the phage infected TG1 cells were incubated at 37° C. for 90 minutes without shaking followed by dilution with 10 ml of 2×YT medium containing 5 µg/ml 40 tetracycline and incubated at 37° C., with shaking at 250 rpm for approximately 16 hours. Phage supernatants were collected after centrifugation and one more round of panning was carried out. Phage titration plates were used for picking the colonies and performing PCR amplification and subse- 45 quent sequencing to establish the identity of the cloned insert. A total of 960 phage clones were sequenced using phage specific primers. The sequences obtained after Sanger's di-deoxy sequencing were analyzed by Pubmed BLAST to identify the *B. microti* antigen it encodes. Finally, 50 the sequencing reads were aligned to the target sequence in MacVector program.

Phage ELISA to Analyze Affinity-Selected Clones

The reactivity of affinity-selected phage supernatants with babesiosis patient sera was measured by ELISA. The wells of maxisorp microwell plates (Immulon 4 HBX, Thermo Scientific, Rochester) were coated with 50 ng/well of anti-M13 phage antibody (GE Healthcare, Piscataway, N.J.) and blocked with 5% skim-milk PBST (0.5% tween-20). Subsequently, phage supernatants of the selected clones were added to each well and incubated for 1 hour at RT. Next, serially diluted sera (in 5% skim-milk PBST) were added and incubated at RT for 1 hour. The bound antibodies were probed with HRP-conjugated goat anti-human IgG antibodies, and the enzymatic activity was revealed by incubating 65 the plates with chromogenic substrate, ABTS (KPL, Inc., Gaithersburg, Md.). The genes encoding the domains with

20

high ELISA reactive phage clones were selected for cloning into an *E. coli* expression system.

Recombinant Expression and Purification of *B. microti* Antigens

Expression of recombinant protein was accomplished by amplifying either the full-length gene or a portion thereof encoding a domain of the protein, predicted based on the theoretical antigenicity index using Immune Epitope Database and Analysis Resource (IEDB). The putative signal and transmembrane sequences were identified using SignalP 4.1 Server and TMHMM Server v. 2.0, respectively, and excised in the domain selected for recombinant expression. The PCR-amplified product was cloned into a NotI and AscI (NEB, Ipswich, Mass.) restriction site in a pET11a vector (MERCK, Germany), which was modified to include a NH₂-terminal hexa-histidine tag to facilitate purification. Protein expression was carried out in E. coli BL-21 (λDE3) cells with isopropyl β-D-1-thiogalactopyranoside (IPTG) induction. Induced E. coli cells were lysed with BUG-BUSTERTM Protein Extraction Reagent (EMD Millipore. MA) and the soluble proteins were purified from the supernatant on a HisTrap column (GE Healthcare life sciences, PA). The insoluble proteins were purified using a method as described by Buchner and Rudolph with some modifications (Buchner and Rudolph, Biotechnology 9:158, 1991). Essentially, the cells were lysed using a combination of lysozyme and sonication, followed by buffer (50 mM Tris pH 8.0, 20 mM EDTA) washing 4-6 times to obtain pure inclusion bodies (IBs). The insoluble protein in the IBs was denatured in the solubilization buffer (0.1M Tris pH 8.0, 2 mM EDTA, 6M Guanidine HCl) before refolding under controlled redox condition in the renaturation buffer (0.1M Tris pH 8.0, 2 mM EDTA, 0.5 M L-Arginine HCl, 0.9 mM oxidized Glutathione). The refolded protein was dialyzed against a gradient of urea and finally brought into 20 mM Tris pH 8.0 buffer and purified on a HisTrap column. The purified recombinant proteins were quantified using Bradford's reagent (Sigma-Aldrich, MO). The degree of purity of recombinant proteins was determined on SDS-PAGE followed by Coomassie blue staining. Mass spectrometry analysis of the purified recombinant B. microti proteins was performed to confirm their identity.

Generation of Antibodies Against Recombinant B. microti Antigens

Female Balb/c mice (5-6 weeks old) were purchased from Jackson Laboratories (Bar Harbor, Mass.). Mice (5 per group) were immunized three times with 50 μg of purified recombinant *B. microti* serine rich antigen (BmSERA), *B. microti* maltese cross form related protein (BmMCFRP) and *B. microti* piroplasma β-strand (BmPiβS) per mouse subcutaneously in Freund's adjuvant (Complete Freund's adjuvant for the primary dose followed by two booster doses in Incomplete Freund's adjuvant) at 3-week intervals. Serum samples were collected two weeks after the third immunization and stored at –20° C. until use.

ELISA

The recombinant *B. microti* antigens were coated overnight (approximately 16 hours) on 96-well maxisorp ELISA plates (Immulon 4 HBX, Thermo Scientific, Rochester) in PBS at 50 ng/well. Plates were washed with PBST (PBS with 0.1% Tween-20) and blocked with blocking buffer (5% skim milk PBS with 0.5% Tween-20) for 2 hours at 37° C. This was followed by washing with PBST. 100-fold diluted serum in blocking buffer was added to the wells and plates were incubated for 1 hour at 37° C., followed by PBST washing and incubating with 1/10,000 diluted HRP-conjugated goat anti-human IgG and IgM antibody for 1 hour at

37° C. Plates were then washed six times with PBST and three times with PBS and then incubated with 50 μ l per well of SureBlue Reserve TMB (KPL Inc.) substrate solution for an additional 10 minutes at RT. The reaction was stopped using 50 μ l per well of stop solution (Thermo Fisher Scientific, MA). The plates were read at 450 nm using plate reader (SpectraMax384, Molecular devices, CA). The assay cutoff was determined from the mean optical density reading for the *B. microti* negative (n=15) serum samples+2 standard deviations of the mean.

Immunofluorescence Assay (IFA)

For IFA, slides were prepared from *B. microti* infected RBCs and reacted with 128-fold diluted human sera for 1 hour at 37° C. in a humidified chamber. This was followed by three washings with PBS in a coplan jar. The bound antibodies were probed using 2000-fold diluted ALEXA FLOURTM 488 conjugated goat anti-human IgG antibody in 0.002% Evan's blue solution made in PBS and the slides were again incubated for 1 hour at 37° C. Finally, the slides were washed three times with PBS in a coplan jar in the dark. The slides were mounted with fluoromount slide mounting medium (Electron microscopy sciences, VWR, PA) and sealed with a coverslip. The slides were observed in a fluorescence microscope at 40× resolution under GFP 25 filter.

Enhanced Chemiluminescence *Babesia microti* ELISA (ECL-BmELISA)

The recombinant BmSERA, BmMCFRP and BmPißS antigens were used to coat the Costar black clear bottom 30 plate (Corning, N.Y.) at 25 ng/well, 50 ng/well and 50 ng/well, respectively, in 1×PBS (10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4). For the combination ELISA, the three antigens (BmSERA, BmMCFRP and BmPiβS) were mixed at the concentration 35 of 25 ng/well, 50 ng/well and 50 ng/well, respectively. The plates were incubated overnight (approximately 16 hours) at 4° C. The plates were taken out and incubated at 37° C. for 1 hour, washed 3 times with PBS containing 0.1% Tween-20 (Thermo Fisher Scientific, MA) and blocked for 2 hours at 40 37° C. with 5% skim milk (Bio-Rad, CA) in 1×PBS with 0.5% Tween-20. Following incubation, the blocking solution was removed by flicking the plates and a 100-fold dilution of the test serum in sample diluent (Blocking buffer with 0.35M NaCl) was added to the wells. The plates were 45 incubated for 1 hour at 37° C. After 3 washings with 1×PBST, 1/10,000 diluted HRP-conjugated goat anti-human IgG and IgM antibody (Jackson Immunoresearch Laboratories, PA) was added and incubated further for 1 hour at 37° C. Finally, the plates were washed 6 times with 1×PBST and 50 3 times with 1×PBS, before adding SuperSignal™ ELISA Pico Chemiluminescent Substrate (Thermo Fisher Scientific, MA) for 5 minutes at room temperature. The chemiluminescence reading was taken on Victor³V 1420 multilabel counter (Perkin Elmer, MA). The results obtained from 55 the reading are in relative light units (RLUs).

ELISA Assay Cutoff Determination

Cutoff value=mean optical density reading for the *B. microti* negative (n=15) serum samples+2 standard deviations of the mean.

Example 2: ECL-ELISA for the Detection of Antibodies to *B. microti* in Blood Donors

This example describes the development of an ELISA to 65 detect *B. microti*-specific antibodies in human serum samples.

22

Immunoscreening of B. microti Antigens

The M13 phage display library displaying the *B. microti* transcriptome was screened with the pooled infected babesiosis patient sera. Following two rounds of panning, a total of 960 clones were isolated and amplified via PCR, before being subjected to nucleotide sequencing. The gene sequences obtained following sequencing were aligned to the target *B. microti* genome, which led to identification of 56 immunodominant *B. microti* antigens. Subsequently, these 56 phage clones displaying distinct *B. microti* antigens were analyzed on a confirmatory phage-ELISA against the pooled infected babesiosis patient sera. A total of 30 high ELISA reactive phage clones displaying specific *B. microti* antigens were selected for antigenic characterization and recombinant expression.

⁵ Antigenic Characterization

Availability of whole genome sequence of B. microti (Cornillot, et al., Nucleic Acids Res 40:9102, 2012) has made in silico analyses of the 30 identified immunodominant antigens feasible. The distribution of the genes encoding these 30 antigens on the chromosomes of B. microti is shown in FIG. 1. The genes identified from the phage library based selection appeared to be randomly distributed on all four chromosomes of B. microti. This demonstrates that the genes encoding the highly antigenic proteins are not localized to the terminal regions, or more specifically, to the highly variable sub-telomeric region as reported previously (Lodes et al., Infect Immun 68:2783, 2000). Most of these antigens have never been characterized and possess an unknown cellular or biological function. Also, none of these antigens share any homology with each other. At the protein level, BmR1_03g00690, antigens, BmR1_03g04855, BmR1_03g06300, BmR1_03g04120 and BmR1_02g04285, are unique only to B. microti. BmR1_02g04285 has high sequence identity to the COOH-terminus region of Maltese cross form related protein. Two of these antigens, BmR1_03g00785 and BmR1_03g04855, are members of the B. microti sero-reactive antigen family (bmn) (Lodes et al., Infect Immun 68:2783, 2000; Homer et al., J Clin Microbiol 38:362, 2000).

Next, the available database (PiroplasmaDB at piroplasmadb.org) was searched to determine the gene copy number of each antigen. Though no estimation of the copy number could be found, the paralogue count for each gene provided a rough estimation for the copy number. Eight of these genes had at least one paralogue. The bmn family members BmR1_03g00785 and BmR1_03g04855 had 9 and 12 paralogues, respectively. BLAST search was performed with 30 high index B. microti antigens to identify their orthologs from other apicomplexans. Twenty of these proteins had orthologous proteins in other apicomplexan parasites, whereas 10 of them yielded no similarity. This shows the uniqueness of the proteins identified and their specificity to B. microti. The results also suggest that B. microti belongs to a distinct lineage of piroplasmida outside the classical Theileria and Babesia genera in the phylogenetic classification.

The *B. microti* proteins identified using phage display as gIII fusion proteins on M13 phages were cloned as NH₂-terminal hexa-histidine tagged in an *E. coli* expression vector for recombinant protein production. Thirty of the most reactive *B. microti* antigens as identified in phage display screening were produced as recombinant proteins in *E. coli*. A map of the protein domain(s) expressed for each identified antigen is shown in FIG. 2.

Bioinformatics Analyses

The four proteins that were identified as antigens in *B. microti* strain RI were subject to in-depth sequence analysis

to obtain a better understanding of their evolutionary history and potential functional features. First, their compositional features were analyzed to predict signal, transmembrane (TM) and low complexity regions. This was followed by in-depth sequence analysis using sequence profile searches with the PSI-BLAST program and hidden Markov model searches using the JACKHMMER program. Finally, profile-profile searches with the HHpred program were conducted to detect even more remote relationships. The analysis of the four proteins revealed that all were predicted to contain 10 N-terminal signal peptides consistent with their cell-surface localization as immunogenic antigens.

BmR1_04g08155 is a 946-amino acid protein, which was erroneously annotated as having "homologies with serinerepeat antigen 4." This annotation is unsupported by 15 sequence analysis and arises from improper masking of low complexity sequence. However, this protein has a previously reported homolog in the Munich strain of B. microti where it was reported to have antigenic properties consistent with the current study (PMID: 20599995). Remarkably, compari- 20 son of BmR1_04g08155 with this protein suggest that it is extremely fast-evolving even between these two strains with a sequence identity just around 43%, which is much higher than the sequence divergence for other available proteins between these two strains (~95-98% identity). This strongly 25 suggests that this protein is evolutionarily responding to host immune responses against it and is consistent with its character as an antigenic secreted/cell surface protein.

BmR1 03g04855 is a member of the so-called "BMN1" class of antigenic proteins, which is shared by different B. 30 microti strains and B. rodhaini. While some of these related antigens (SA5-1-1, SA26 and SA17) were first identified in B. rodhaini in 1988 (PMID: 2893977), several subsequent studies in B. microti have misunderstood the evolutionary relationships of these proteins resulting in considerable 35 confusion in their nomenclature in the literature (PMID: 12574273, 10768973, 23291346, 27184823). The sequence analysis disclosed herein shows that the proteins which have been considered BMN1 antigens do not constitute a monophyletic group and should have been included together for 40 construction of phylogenetic trees. Instead the present analysis shows that there are two mostly evolutionarily unrelated groups of BMN1 proteins. The first of these groups includes the previously characterized BMN1-10, N1-10, BMN1-4, BMN1-3B, BMN1-8 and BMN1-11 from the B. microti 45 MN1 strain, the IRA protein from the B. microti Gray strain and the Br-1 and Br-2 proteins from the B. rodhaini Japan strain. The second major group is comprised of BMN1-2, BMN1-3, BMN1-6, BMN1-7, BMN1-9, BMN1-13, BMN1-4, MN-10 and N1-21 from the B. microti MN1 strain, 50 BmSA1 from the *B. microti* Gray strain, BmP32 from the *B.* microti Munich strain, MSA1 and MSA2 from the B. rodhaini Australia strain and Br-1, p25 and p26 from the B. rodhaini Japan strain. Beyond these, the proteins BMN1-17 and BMN1-20 are paralogs that are unrelated to any of the 55 above groups, and likewise BMN1-15 is unrelated to any of these other proteins. Hence, it is strongly recommended that henceforth the BMN1 be treated as distinct groups as per their evolutionary relationships.

The analysis herein showed that BmR1_03g04855 from 60 the *B. microti* R1 strain belongs to the first of the major groups (i.e. BMN1-10 and its relatives). *B. microti* R1 has a total of 10 members of this group. Analysis of these proteins shows that they are characterized by the presence of a conserved domain which might be present in one to five 65 copies per protein, with a single copy in BmR1_03g04855. Secondary structure prediction based on an alignment of this

24

domain showed that it contains an N-terminal region with eight conserved β-strands followed by a C-terminal region with multiple cysteines. The N-terminal region is likely to adopt a β-sandwich fold whereas the C-terminal region is likely to adopt a disulfide bond supported structure. Iterative sequence profile analysis identified proteins with a divergent version of this domain outside of Babesia in a group of secreted proteins in Theileria. While this family is expanded across Theileria (it is particularly abundant in the horseparasitic species T. equi, about 460 members), it is present in fewer numbers in T. annulata, T. orientalis, T. parva. As it is present in both the piroplasms, this domain was named the piroplasm β-strand (PiβS) domain. Given that the PiβS family is inferred to have been ancestrally present in the piroplasms, it is likely that it has played an important role in host-parasite dynamics of the entire piroplasm lineage. Importantly, the phylogenetic analysis of the PiβS domain in the genus *Babesia* showed that its evolution is dominated by lineage-specific expansions. Notably, the versions in B. rodhaini appear to have radiated entirely independently of those from B. microti. Moreover, even within B. microti, clades exclusively or predominantly containing R1 strain or MN1 strain proteins were found.

BMR1_02g04285 is a hypothetical protein of 177 amino acid length with homologies to maltese cross form related protein (GenBank accession no. AB079857.1). The protein is potentially involved in cytoskeleton remodeling, which provides evidence for its localization to be on the cell surface.

This suggests that these antigens have been evolving at very short evolutionary distances via independent lineage-specific expansions. Such a pattern is a hallmark of an arms race with the host and has been observed before in the case of other apicomplexan surface proteins such as the rifin-like and the var/DBL1 superfamilies in *Plasmodium falciparum*; and the vir/yir superfamilies in *P. vivax/P. yoelii*. This suggests that the Pi β S and BAHCS domain families are similarly likely to be expressed on the cell-surface at the interface with the host immune system. The dynamic evolution suggests that the lineage-specific expansions are a positively selected response against the host immunity targeting them.

5 Characterization of Recombinant B. microti Antigens

The recombinant proteins BmSERA, BmPißS and BmMCFRP consisted of 376, 252 and 177 amino acid residues, respectively, with an additional sequence to include the hexa-histidine tag and a spacer, resulting in calculated molecular weights of 44, 32 and 23 kDa, respectively. The cDNA and amino acid sequences of BmSERA, BmPiβS and BmMCFRP are shown below. Protein characterization was done on 4-12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) following Coomassie blue staining (SimplyBlue SafeStain; Thermo Fisher Scientific, MA) (FIG. 3). Results showed that the purified proteins were highly pure with no visible contaminating bands. Recombinant BmMCFRP and BmPißS demonstrated a gel mobility at the predicted molecular weight of ~25 kDa and ~35 kDa, respectively, on SDS-PAGE, whereas BmSERA showed a protein band at 65 kDa molecular weight. Protein mass spectrometry analysis of the purified recombinant B. microti proteins was performed to validate their identity. Results showed high sequence identity of the recombinant protein with the corresponding B. microti anti-

-continued

BmSERA: (SEQ ID NO: GCTAAGCAGACTTTCATCAAAAACAAATCTCTCACTAATCCTGGCGTG GACAATCCGAACTTATCTGAAGGAGTCGTTCCATCCGATGAACATATT TCTTCGCAATCCCAAATCCAACTTTTGAGCCCACTAGCAACACCATTT CAAGTGATACATCTCAACCAATCAACCAACCAACCAATCAACCAACCA ACCAACCAACCAATCAACCAATCAACCAACCAATCAACCAATCA ACCAACCAACCAACCAACCAACCAACCACCAACCAACCA ACCAGTCAACCAACCAATCAACCAGTCAACCAACCAATCAACCAGTCA ACCAACCAAACAACCAATCAGTCAACCAACCAACCAATCAACCAATCA ACCAACCAATCAACCAGTCAACCAACCAACCAATCAGTCAACCA GCTGAAACCATGAGTCCTGCGCCCCTATTCGTTGAAGTTGACATCCTG AATGCTATTATGTTTGTCCGCGTCGCTAGAAACATGGCCTCAAACATC ATAATTAAAAGTGTAAAGGTTGGAGAAGATATTTTGTATTTAAATGAT CGAAGACTTGACCTAATTCTTGAATTTACAGTTACTTCTCAACAGGGT TTCCATATGAGGATCTACAATAATGATGATCGTACGGAGAATGGTGTT ATCGGCTTTCTTTGTTCTTTCATAGTTGCAGATCATATTCCTAAGTGG

(SEQ ID NO: AKQTFIKNKSLTNPGVDNPNLSEGVVPSDEHISSQSQIQLLSPLATPF QVIHLNQSTNQPINQPTNQPVNQPTNQSTNQPTNQPTNQPTNQSTNQP TNQPNQPTNQSTNQPTNQSTNQPTNQPTNQSTKQP TNQPVNQPINQSTKQPVNQPINQSTKQPNQPINQSTNQPVNQPINQS TNQTTNQSTNQPINQSTKQPTKQPTNQPNNQTTNQSTSQPTKQPISQP INQPNNIMGDKRGLKGAETMSPAPLFVEVDILKDSLDSNLEVLYQVSV NAIMFVRVARNMASNIIIKSVKVGEDILYLNDRRLDLILEFTVTSQQG FHMRIYNNDDRTENGVIGFLCSFIVADHIPKWYNPPNSRR

TACAATCCACCTAACTCACGCCGT

BmMCFRP:

(SEQ ID NO: TGTGATGATATTGGTAGGGCTAATCATAACCCCAATATACATAACTAT CCCGCATTTTTAGAACCGATAGACATCGACATAAAGTCCACACCAGTA CCGAAGGATGTTGACAACGGTGTTTTTAAGTTAGCTGGTAGT CGCAAGACGGAATTGAAACTCAGACCAAAAGTTGGGGGCAAGTACTTG GAGGTCTCCCTCATGTTGCCGTCGTTCAAGTTTCCGTTTCCGTTTCC

- GATGGAATAATAAACGTCTACGAAGATGACTACCACAAAATTACTGTG

 AAGCAATTCGACATGGATGGGAATATCATTATTAAACAAAGGGAAGGT

 GCAATTTCGGCTCATCCATTTGCACAATTGGCATTCTCTGTTGCATCA

 TCTGCAAACAATGTTATTTTAGAGGAAAATGAAATCTTAAAGAAGAAT

 ATTCTCGAAGATAACAAAGATAATAGTCAATCAGACGGGGAAATTGCT

 TCTGAACAAGAAAAAACTAGCACTTTATCATTCCCATCATCGCCATCA

 TCA
- (SEQ ID NO: 4)

 15 CDDIGRANHNPNIHNYPAFLEPIDIDIKSTPVPKDVEFDNGVFKLAGS

 RKTELKLRPKVGGKYLEVSPHVAVVQVSVSVSDGIINVYEDDYHKITV

 KQFDMDGNIIIKQREGAISAHPFAQLAFSVASSANNVILEENEILKKN

 ILEDNKDNSQSDGEIASEQEKTSTLSFPSSPSS

BmPißS:

2)

- (SEO ID NO: 5) CCATCAAATGGCCTCTATGAATCTAACCTTTTTTACACGGAAGGTTAT GGCAAATATTTGACTAGTCCGACTAAGATAAAGACAATTGAATTTGGA GGTTATAAATTCGAGTTTGATGATGATACATTGCCTGTAACATCTATA ACAAAAATCGATGTAATAACATATGATGATAAACCGATTTTATTTGAA TTTATTTCAGATAAGGATCGTCCATACAGAAGATTTTACTACTATACT TTGGATAGTAAAACTAATAAATTATATATATGTCACTGCAGAAACT GGATATAATGTTGAGGATTCGAGTGGTCTAAAATACTACACTGAATTA AGTAAATCGGGAATAAATGATGTTTTTACAAGATTTGGATAAAAACATT GATGAAAGTAATATCGAGCATTTGAAGACATCATATGTAACAAAAGGA TTAAATATTGCGATTGAAGTTTATTCAAACAGAGTCGTTGAACAAATT AAATCGATAAAGGTAGTTACTCCAGTTGAATTATTCGATTATAAAACT GAAGTTCCAATTGAGTCTGTAGATCATGAATCGCGTGATAATTCATTG GCCGAAGTAGAGGAGGATGGAAAAGCTGTACAAGTTGGGACTCAACCT GTGTATGAGGTAAATGATGGTGCTCATAACCCATCTGCACAAGTGTTA TCACAGAATAATATTATTGAGACCTTGGATGATAAATCTAAAGTTACT CATTTGAGAAATGCTGGCAGTGAGAAAATTCGTGTT
- 50 (SEQ ID NO: 6)
 PSNGLYESNLFYTEGYGKYLTSPTKIKTIEFGGYKFEFDDDTLPVTSI

 TKIDVITYDDKPILFEFISDKDRPYRRFYYYTLDSKTNKLYNYVTAET
 GYNVEDSSGLKYYTELSKSGINDVLQDLDKNIDESNIEHLKTSYVTKG

 LNIAIEVYSNRVVEQIKSIKVVTPVELFDYKTEVPIESVDHESRDNSL
 AEVEEDGKAVQVGTQPVYEVNDGAHNPSAQVLSQNNIIETLDDKSKVT
 HLRNAGSEKIRV
- ELISA Evaluation of *B. microti* Recombinant Antigens
 To evaluate the immunodominant antigens identified through phage display as potential screening markers for babesia, ELISA reactivity of the recombinant proteins
 against *B. microti*-infected sera was assessed. Table 1 shows ELISA screening results against sera from patients with clinical babesiosis and from healthy individuals on plates

nodominant B. microti antigens. The pattern of reactivity of these antigens are different and not a single antigen is able

to detect all of the clinical sera (FIG. 4). The sensitivity of

antigens according to the number of clinical samples recognized. The three highest reactivity antigens were combined in a single well following an extensive standardization

experiment to establish the coating concentration of an

individual antigen without loosing the sensitivity of an individual antigen in combination. A total of 28 babesiosis

patient sera were used to determine the sensitivity of ECL-

BmELISA against BmSERA, BmMCFRP and BmPißS anti-

antibodies in serum samples. The following ELISA results were obtained: BmSERA: 93%; BmMCFRP: 75%; and BmPiβS: 73%. When a combination of the 3 antigens were

used 27/28 (96%) of serum samples were found positive for B. microti antibodies (Table 2). These results showed that 20

combining multiple antigens in a single well enhanced the sensitivity and robustness of B. microti antibody detection

by ECL-BmELISA. For specificity determination, serum

samples from 15 United States blood donors were tested in

and BmPißS and a combination of the 3 antigens. As shown

in the Table 2, all 15 of the serum samples (100%) were

negative in ECL-BmELISA using either three individual or

ECL-BmELISA against individual BmSERA, BmMCFRP 25

TABLE 2

ECL-BmELISA assay sensitivity and specificity the antigens varied and allowed specific classification of the 5 Number of human serum samples Babesia microti Normal human Antigen positive serum **BmSERA** 25/28 (89%) 0/15 BmMCFRP 19/28 (68%) 0/15 BmPiβS 0/15 20/28 (71%) gens and combination antigens in detection of B. microti $_{15}$ BmSERA + BmMCFRP + BmPiβS 27/28 (96%) 0/15

Nucleotide Diversity

To determine whether the three chosen molecules (Bm-SERA, BmPißS and BmMCFRP) are strongly conserved and represent appropriate diagnostic targets, studies were performed to determine the nucleotide diversity naturally existing in the population. To achieve this, alignments were generated of nucleotide sequences from 41 samples (available on Piroplasmadb.org), including 36 human B. microti clinically infected cases, two samples from infected Ixodus ticks and four from infected rodents, and then compared to the laboratory adapted B. microti Peabody strain (used for phage library construction and gene cloning in the current study) that was isolated in Nantucket in 1973 for the determination of nucleotide and amino acid polymorphisms (Lemieux et al., Nat Microbiol 1(7):16079, 2016). The full length BmSERA, BmPißS and BmMCFRP have a total of 130, 37 and 35 SNPs (single nucleotide polymorphisms) with non-synonymous to synonymous substitution ratio (dN/dS) of 3.06, 1.64 and 3.38, respectively. However, for the present study, only the immunodominant region of these 40 proteins were cloned, calculated based on the theoretical antigenicity index, which has comparatively lowered the nucleotide variation to 46, 18 and 35 SNPs and dN/dS ratio of 2.5, 1.6 and 1.3 respectively, for BmSERA, BmPißS and BmMCFRP. The nucleotide variation reported here as SNPs 45 are mostly due to the B. microti Russia-1995 strain, which is reported to be highly variable at the genomic level relative to the strains isolated from the continental United States (Lemieux et al., Nat Microbiol 1(7):16079, 2016).

In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

TABLE 1 Results of BmELISA assay to determined the sensitivity of B. microti proteins

combination antigens.

	Number of hum	an serum samples
Antigen	Babesia microti positive	Normal human serum
BmBAHCS	27/28 (96%)	0/15
(BmR1_03g00785)	` ′	
BmSERA (BmR1_04g08155)	24/28 (86%)	0/15
BmMCFRP	23/28 (82%)	0/15
(BmR1_02g04285)		
BmPiβS (BmR1_03g04855)	22/28 (79%)	0/15
BmEGF (BmR1_03g00690)	19/28 (68%)	0/15
BmR1_01g03455	19/28 (68%)	0/15
BmR1_02g00670	19/28 (68%)	0/15
BmR1_03g03490	17/28 (61%)	0/15
BmR1_04g06300	16/28 (57%)	0/15
BmR1_02g03965	14/28 (50%)	0/15
BmR1_01g01125	13/28 (46%)	0/15
BmR1_04g08775	12/28 (43%)	0/15
BmR1_02g02760	11/28 (39%)	0/15
BmR1_04g07910	10/28 (36%)	0/15
BmR1_03g00420	10/28 (36%)	0/15
BmR1_02g03700	8/28 (29%)	0/15
BmR1_01g01620	6/28 (21%)	0/15
BmR1_04g09905	5/28 (18%)	0/15
BmR1_02g02985	4/28 (14%)	0/15

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1 <211> LENGTH: 1128

<212> TYPE: DNA

<213> ORGANISM: Babesia microti

-continued

<400> SEQUENCE: 1 gctaagcaga ctttcatcaa aaacaaatct ctcactaatc ctggcgtgga caatccgaac 60 ttatctgaag gagtcgttcc atccgatgaa catatttctt cgcaatccca aatccaactt 120 ttgagcccac tagcaacacc atttcaagtg atacatctca accaatcaac caaccaacca atcaaccaac caaccaatca accagtcaac caaccaacca accaatcaac caaccaacca accaaacaac caaccaacca accagtcaac caaccaaaca accagtcaac caaccaacca 480 540 accaatcaac cagtcaacca accaatcaac cagtcaacca accaaacaac caatcagtca 600 660 aacaaccaaa caaccaacca atcaaccaqt caaccaacca aacaaccaat caqtcaacca 720 atcaaccaac caaacaatat aatqqqaqat aaqcqqqqcc tcaaaqqcqc tqaaaccatq 780 aqtcctqcqc ccctattcqt tqaaqttqac atcctqaaaq attctttqqa taqtaactta 840 gaagtattat atcaagttag tgttaatgct attatgtttg tccgcgtcgc tagaaacatg 900 gcctcaaaca tcataattaa aagtgtaaag gttggagaag atattttgta tttaaatgat 960 cgaagacttg acctaattct tgaatttaca gttacttctc aacagggttt ccatatgagg 1020 atctacaata atgatgateg taeggagaat ggtgttateg getttetttg ttettteata 1080 gttgcagatc atattcctaa gtggtacaat ccacctaact cacgccgt 1128 <210> SEQ ID NO 2 <211> LENGTH: 376 <212> TYPE: PRT <213> ORGANISM: Babesia microti <400> SEOUENCE: 2 Ala Lys Gln Thr Phe Ile Lys Asn Lys Ser Leu Thr Asn Pro Gly Val Asp Asn Pro Asn Leu Ser Glu Gly Val Val Pro Ser Asp Glu His Ile Ser Ser Gln Ser Gln Ile Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu Asn Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Val Asn Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr Asn Gln Pro Thr Asn Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro 90 Thr Asn Gln Pro Asn Asn Gln Pro Thr Asn Gln Ser Thr Lys Gln Pro Thr Asn Gln Pro Val Asn Gln Ser Thr Asn Gln Pro Ile Asn Gln Ser 120 Thr Lys Gln Pro Asn Asn Gln Pro Ile Asn Gln Ser Thr Lys Gln Pro 135

Thr Asn Gln Pro Val Asn Gln Pro Asn Asn Gln Ser Thr Asn Gln Pro

150

155

-continued

Thr Asn Gln Pro Ile Asn Gln Thr Thr Asn Gln Pro Asn Asn Gln Pro 165 170 Thr Ser Gln Pro Thr Asn Gln Pro Val Asn Gln Pro Ile Asn Gln Ser 185 Thr Asn Gln Thr Thr Asn Gln Ser Thr Asn Gln Pro Ile Asn Gln Ser 200 Thr Lys Gln Pro Thr Lys Gln Pro Thr Asn Gln Pro Asn Asn Gln Thr Thr Asn Gln Ser Thr Ser Gln Pro Thr Lys Gln Pro Ile Ser Gln Pro Ile Asn Gln Pro Asn Asn Ile Met Gly Asp Lys Arg Gly Leu Lys Gly Ala Glu Thr Met Ser Pro Ala Pro Leu Phe Val Glu Val Asp Ile Leu Lys Asp Ser Leu Asp Ser Asn Leu Glu Val Leu Tyr Gln Val Ser Val Asn Ala Ile Met Phe Val Arg Val Ala Arg Asn Met Ala Ser Asn Ile Ile Ile Lys Ser Val Lys Val Gly Glu Asp Ile Leu Tyr Leu Asn Asp 310 Arg Arg Leu Asp Leu Ile Leu Glu Phe Thr Val Thr Ser Gln Gln Gly 330 Phe His Met Arg Ile Tyr Asn Asn Asp Asp Arg Thr Glu Asn Gly Val 345 Ile Gly Phe Leu Cys Ser Phe Ile Val Ala Asp His Ile Pro Lys Trp Tyr Asn Pro Pro Asn Ser Arg Arg 370 <210> SEQ ID NO 3 <211> LENGTH: 531 <212> TYPE: DNA <213> ORGANISM: Babesia microti <400> SEQUENCE: 3 tgtgatgata ttggtagggc taatcataac cccaatatac ataactatcc cgcattttta gaaccgatag acatcgacat aaagtccaca ccagtaccga aggatgttga gtttgacaac ggtgttttta agttagctgg tagtcgcaag acggaattga aactcagacc aaaagttggg ggcaagtact tggaggtete teeteatgtt geegtegtte aagttteegt tteegtttee gatggaataa taaacgtcta cgaagatgac taccacaaaa ttactgtgaa gcaattcgac atggatggga atatcattat taaacaaagg gaaggtgcaa tttcggctca tccatttgca caattggcat tctctgttgc atcatctgca aacaatgtta ttttagagga aaatgaaatc 420 ttaaaqaaqa atattetega aqataacaaa qataataqte aateaqaeqq qqaaattqet totgaacaag aaaaaactag cactttatca ttoccatcat cgccatcatc a 531 <210> SEQ ID NO 4 <211> LENGTH: 177 <212> TYPE: PRT <213> ORGANISM: Babesia microti <400> SEQUENCE: 4 Cys Asp Asp Ile Gly Arg Ala Asn His Asn Pro Asn Ile His Asn Tyr

-continued

Pro Ala Phe Leu Glu Pro Ile Asp Ile Asp Ile Lys Ser Thr Pro Val 25 Pro Lys Asp Val Glu Phe Asp Asn Gly Val Phe Lys Leu Ala Gly Ser Arg Lys Thr Glu Leu Lys Leu Arg Pro Lys Val Gly Gly Lys Tyr Leu Glu Val Ser Pro His Val Ala Val Val Gln Val Ser Val Ser Val Ser Asp Gly Ile Ile Asn Val Tyr Glu Asp Asp Tyr His Lys Ile Thr Val Lys Gln Phe Asp Met Asp Gly Asn Ile Ile Ile Lys Gln Arg Glu Gly Ala Ile Ser Ala His Pro Phe Ala Gln Leu Ala Phe Ser Val Ala Ser Ser Ala Asn Asn Val Ile Leu Glu Glu Asn Glu Ile Leu Lys Lys Asn Ile Leu Glu Asp Asn Lys Asp Asn Ser Gln Ser Asp Gly Glu Ile Ala 145 Ser Glu Gln Glu Lys Thr Ser Thr Leu Ser Phe Pro Ser Ser Pro Ser 170 Ser <210> SEQ ID NO 5 <211> LENGTH: 756 <212> TYPE: DNA <213> ORGANISM: Babesia microti <400> SEOUENCE: 5 ccatcaaatg gcctctatga atctaacctt ttttacacgg aaggttatgg caaatatttg 60 actagtccga ctaagataaa gacaattgaa tttggaggtt ataaattcga gtttgatgat 120 gatacattgc ctgtaacatc tataacaaaa atcgatgtaa taacatatga tgataaaccg 180 attttatttg aatttatttc agataaggat cgtccataca gaagatttta ctactatact 240 ttggatagta aaactaataa attatataat tatgtcactg cagaaactgg atataatgtt 300 gaggattcga gtggtctaaa atactacact gaattaagta aatcgggaat aaatgatgtt 360 ttacaagatt tggataaaaa cattgatgaa agtaatatcg agcatttgaa gacatcatat 420 gtaacaaaag gattaaatat tgcgattgaa gtttattcaa acagagtcgt tgaacaaatt aaatcgataa aggtagttac tccagttgaa ttattcgatt ataaaactga agttccaatt gagtetgtag ateatgaate gegtgataat teattggeeg aagtagagga ggatggaaaa gctgtacaag ttgggactca acctgtgtat gaggtaaatg atggtgctca taacccatct qcacaagtgt tatcacagaa taatattatt gagacettgg atgataaate taaagttact 720 catttgagaa atgctggcag tgagaaaatt cgtgtt <210> SEQ ID NO 6 <211> LENGTH: 252 <212> TYPE: PRT <213> ORGANISM: Babesia microti <400> SEQUENCE: 6 Pro Ser Asn Gly Leu Tyr Glu Ser Asn Leu Phe Tyr Thr Glu Gly Tyr 10 Gly Lys Tyr Leu Thr Ser Pro Thr Lys Ile Lys Thr Ile Glu Phe Gly 20 25

-continued

_															
Gly	Tyr	Lув 35	Phe	Glu	Phe	Asp	Asp 40	Asp	Thr	Leu	Pro	Val 45	Thr	Ser	Ile
Thr	Lys 50	Ile	Asp	Val	Ile	Thr 55	Tyr	Asp	Asp	Lys	Pro 60	Ile	Leu	Phe	Glu
Phe 65	Ile	Ser	Asp	Lys	Asp 70	Arg	Pro	Tyr	Arg	Arg 75	Phe	Tyr	Tyr	Tyr	Thr 80
Leu	Asp	Ser	Lys	Thr 85	Asn	Lys	Leu	Tyr	Asn 90	Tyr	Val	Thr	Ala	Glu 95	Thr
Gly	Tyr	Asn	Val 100	Glu	Asp	Ser	Ser	Gly 105	Leu	Lys	Tyr	Tyr	Thr 110	Glu	Leu
Ser	Lys	Ser 115	Gly	Ile	Asn	Asp	Val 120	Leu	Gln	Asp	Leu	Asp 125	Lys	Asn	Ile
Asp	Glu 130	Ser	Asn	Ile	Glu	His 135	Leu	Lys	Thr	Ser	Tyr 140	Val	Thr	ГÀа	Gly
Leu 145	Asn	Ile	Ala	Ile	Glu 150	Val	Tyr	Ser	Asn	Arg 155	Val	Val	Glu	Gln	Ile 160
ГÀв	Ser	Ile	Lys	Val 165	Val	Thr	Pro	Val	Glu 170	Leu	Phe	Asp	Tyr	Lys 175	Thr
Glu	Val	Pro	Ile 180	Glu	Ser	Val	Asp	His 185	Glu	Ser	Arg	Asp	Asn 190	Ser	Leu
Ala	Glu	Val 195	Glu	Glu	Asp	Gly	Lys 200	Ala	Val	Gln	Val	Gly 205	Thr	Gln	Pro
Val	Tyr 210	Glu	Val	Asn	Asp	Gly 215	Ala	His	Asn	Pro	Ser 220	Ala	Gln	Val	Leu
Ser 225	Gln	Asn	Asn	Ile	Ile 230	Glu	Thr	Leu	Asp	Asp 235	ГÀа	Ser	ГÀз	Val	Thr 240
His	Leu	Arg	Asn	Ala 245	Gly	Ser	Glu	Lys	Ile 250	Arg	Val				
<211	L> LE	ENGTI) NO												
	2 > T? 3 > OF			Babe	esia	mic	roti								
< 400)> SI	EQUEI	ICE:	7											

atggtacaca taactaataa aaagatcctc tacataactg caggttcctt tcttttgcta 60 acgacaataa ttttgccatt agcattgata tttccaaaat catctgtaga gtttgttgac 120 ctgcatttat ccgacaatct tcccaaatat tacagcattc aatatacgca aaatagactt 180 caaattaaaa taaatgatga attttctgat aaatttttca ttaagaaagt cttcatgcct aatgaaacga ccgtttttga aattgaaggg aataaatcag ccgttataaa catcaaattt tctggtgata cattcaaatt caatatcctt gatattgaaa agtctacata tacagaatac 360 gatggtattc acatagaaga tgacaattcg tggatcttat atgccattgg attggtcaag 420 ccatttcctc gtgttgaagt tgattattct attgaaaagg tgaacttccg tatctcagaa 480 aaaatgcccc ttaattacat cctcgtaaat tcaattgacg gtgtatattt tgctttagat 540 ggcattatta atctgtcaag cattggaaac gtatacgtag acgaagattt tgtaccattg 600 cctaagggat ccaagttgag aacagttcat ataaatactc agtacatctt gagtgtaatt 660 gacttatacg atggatatta taagatttct tactccaagt tcgttgatcc tgttaaacta 720 ccagtctcaa tctcaagtgt catttccatt agttctgcct ttaaaacagt cagcttaaaa 780 gagttettea tgeaatatat atataceata ategattata aaaatatgta tegetetgaa 840

-continued

```
ttggtgaaat tctggctgga cctttccagt aaaaatgtct ttgctgatat tgatgttttg
                                                               900
atgttaaatg gatacatata tatgtatacc ccaaatccca actacaacat tggagcttta
                                                               960
acagtcgggg agacggtgtt gtatcaaggc gatccaattt cacgctctag ggccgtatta
                                                              1020
ctcaagaata tttccggcga atggtatgct atggtggtcg atgtataccc tcattttgat
                                                               1080
atgatcaatc gcggcctttc gcccctgaaa aagatgaatg gtatggattt atttctagag
                                                               1140
aatttgaaca gagtgtattt aaaaaaattt aaccataaat tacctgatgc tacaagcaaa
                                                               1200
caattaacaa cactetetga tggtateaaa gaactagagt taattttegg aagetttgae
gagtccccca tcgatgttta caacatacgt atattgacag attccgcttt aacccaaaag
                                                              1320
tacttgaagg agtatgcgag cattattatg gacattgacc ttgatgtgga tgttttgccg
cccgaagtag aatgtatcac gggggattta ctgctgttga caactttgga tctgaaaaaa
ttagatttca aaattattgg gcgtgtaaaa tggggagaac atatcattga acccaaagcc
                                                              1500
acquetetee tgcgqtcaat tettatattg cacqttaata ccqqctatqt qttttqtqte
                                                              1560
ategatgttg acatetaege taaaateaac gteeetggea tetategage geetgataaa
                                                              1620
ctccccaaat ggatcaaacc cttgccgata atccctatta ttggattgaa agagcctctt
                                                              1680
tcttggggca tatcaactat ccgctatttt gctaagcaga ctttcatcaa aaacaaatct
                                                              1740
ctcactaatc ctggcgtgga caatccgaac ttatctgaag gagtcgttcc atccgatgaa
                                                              1800
catatttctt cqcaatccca aatccaactt ttqaqcccac taqcaacacc atttcaaqtq
                                                              1860
atacatetea accaateaac caaccaacca ateaaccaac caaccaatea accaqteaac
                                                              1920
1980
2040
caaccaacca accaaccagt caaccaatca accaaccaac caatcaacca atcaaccaaa
                                                              2100
2160
caaccaaaca accagtcaac caaccaacca accaatcaac caatcaacca aacaaccaat
                                                              2220
caaccaaaca accaaccaac cagtcaacca accaatcaac cagtcaacca accaatcaac
                                                              2280
cagtcaacca accaaacaac caatcagtca accaaccaac caatcaacca atcaaccaaa
                                                              2340
                                                               2400
caaccaacca aacaaccaac caaccaacca aacaaccaaa caaccaacca atcaaccaqt
caaccaacca aacaaccaat cagtcaacca atcaaccaac caaacaatat aatgggagat
                                                               2460
aageggggcc teaaaggege tgaaaceatg agteetgege eestattegt tgaagttgae
                                                               2520
atcctgaaag attctttgga tagtaactta gaagtattat atcaagttag tgttaatgct
                                                               2580
attatgtttg tccgcgtcgc tagaaacatg gcctcaaaca tcataattaa aagtgtaaag
gttggagaag atattttgta tttaaatgat cgaagacttg acctaattct tgaatttaca
gttacttctc aacagggttt ccatatgagg atctacaata atgatgatcg tacggagaat
                                                              2760
qqtqttatcq qctttctttq ttctttcata qttqcaqatc atattcctaa qtqqtacaat
                                                               2820
ccacctaact cacgccgtta a
                                                              2841
```

```
<210> SEQ ID NO 8
```

Met Val His Ile Thr Asn Lys Lys Ile Leu Tyr Ile Thr Ala Gly Ser 1 5 10 15

<211> LENGTH: 946

<212> TYPE: PRT

<213> ORGANISM: Babesia microti

<400> SEQUENCE: 8

Phe	Leu	Leu	Leu 20	Thr	Thr	Ile	Ile	Leu 25	Pro	Leu	Ala	Leu	Ile 30	Phe	Pro
Lys	Ser	Ser 35	Val	Glu	Phe	Val	Asp 40	Leu	His	Leu	Ser	Asp 45	Asn	Leu	Pro
Lys	Tyr 50	Tyr	Ser	Ile	Gln	Tyr 55	Thr	Gln	Asn	Arg	Leu 60	Gln	Ile	Lys	Ile
Asn 65	Asp	Glu	Phe	Ser	Asp 70	Lys	Phe	Phe	Ile	Lys 75	ГÀЗ	Val	Phe	Met	Pro 80
Asn	Glu	Thr	Thr	Val 85	Phe	Glu	Ile	Glu	Gly 90	Asn	Lys	Ser	Ala	Val 95	Ile
Asn	Ile	Lys	Phe 100	Ser	Gly	Asp	Thr	Phe 105	Lys	Phe	Asn	Ile	Leu 110	Asp	Ile
Glu	Lys	Ser 115	Thr	Tyr	Thr	Glu	Tyr 120	Asp	Gly	Ile	His	Ile 125	Glu	Asp	Asp
Asn	Ser 130	Trp	Ile	Leu	Tyr	Ala 135	Ile	Gly	Leu	Val	Lys 140	Pro	Phe	Pro	Arg
Val 145	Glu	Val	Asp	Tyr	Ser 150	Ile	Glu	Lys	Val	Asn 155	Phe	Arg	Ile	Ser	Glu 160
ГÀа	Met	Pro	Leu	Asn 165	Tyr	Ile	Leu	Val	Asn 170	Ser	Ile	Asp	Gly	Val 175	Tyr
Phe	Ala	Leu	Asp 180	Gly	Ile	Ile	Asn	Leu 185	Ser	Ser	Ile	Gly	Asn 190	Val	Tyr
Val	Asp	Glu 195	Asp	Phe	Val	Pro	Leu 200	Pro	Lys	Gly	Ser	Lys 205	Leu	Arg	Thr
Val	His 210	Ile	Asn	Thr	Gln	Tyr 215	Ile	Leu	Ser	Val	Ile 220	Asp	Leu	Tyr	Asp
Gly 225	Tyr	Tyr	Lys	Ile	Ser 230	Tyr	Ser	Lys	Phe	Val 235	Asp	Pro	Val	Lys	Leu 240
Pro	Val	Ser	Ile	Ser 245	Ser	Val	Ile	Ser	Ile 250	Ser	Ser	Ala	Phe	Lys 255	Thr
Val	Ser	Leu	Lys 260	Glu	Phe	Phe	Met	Gln 265	Tyr	Ile	Tyr	Thr	Ile 270	Ile	Asp
Tyr	Lys	Asn 275	Met	Tyr	Arg	Ser	Glu 280	Leu	Val	Lys	Phe	Trp 285	Leu	Asp	Leu
Ser	Ser 290	ràa	Asn	Val	Phe	Ala 295	Asp	Ile	Asp	Val	Leu 300	Met	Leu	Asn	Gly
Tyr 305	Ile	Tyr	Met	Tyr	Thr 310		Asn	Pro		Tyr 315		Ile	Gly	Ala	Leu 320
Thr	Val	Gly	Glu	Thr 325	Val	Leu	Tyr	Gln	Gly 330	Asp	Pro	Ile	Ser	Arg 335	Ser
Arg	Ala	Val	Leu 340	Leu	ГÀа	Asn	Ile	Ser 345	Gly	Glu	Trp	Tyr	Ala 350	Met	Val
Val	Asp	Val 355	Tyr	Pro	His	Phe	360	Met	Ile	Asn	Arg	Gly 365	Leu	Ser	Pro
Leu	Lys 370	Lys	Met	Asn	Gly	Met 375	Asp	Leu	Phe	Leu	Glu 380	Asn	Leu	Asn	Arg
Val 385	Tyr	Leu	ГÀз	Lys	Phe 390	Asn	His	Lys	Leu	Pro 395	Asp	Ala	Thr	Ser	Lys 400
Gln	Leu	Thr	Thr	Leu 405	Ser	Asp	Gly	Ile	Lys 410	Glu	Leu	Glu	Leu	Ile 415	Phe
Gly	Ser	Phe	Asp 420	Glu	Ser	Pro	Ile	Asp 425	Val	Tyr	Asn	Ile	Arg 430	Ile	Leu
Thr	Asp	Ser	Ala	Leu	Thr	Gln	Lys	Tyr	Leu	Lys	Glu	Tyr	Ala	Ser	Ile

-continued

Hard Het Asp Ile Asp Leu Asp Val Asp Val Leu Pro Asp Leu Lys	Lys 480 Ile
450	Lys 480 Ile
465 Leu Asp Phe Lys Ile Ile Gly Arg Val Lys Trp Gly Glu His Ile 495 Glu Pro Lys Ala Thr Thr Leu Leu Arg Ser Ile Leu Ile Leu His 500 Asn Thr Gly Tyr Val Phe Cys Val Ile Asp Val Asp Ile Tyr Ala 525 Ile Asn Val Pro Gly Ile Tyr Arg Ala Pro Asp Lys Leu Pro Lys 530 Ile Lys Pro Leu Pro Ile Ile Pro Ile Ile Gly Leu Lys Glu Pro 545 Ser Trp Gly Ile Ser Thr Ile Arg Tyr Phe Ala Lys Gln Thr Phe 565 Lys Asn Lys Ser Leu Thr Asn Pro Gly His Ile Ser Ser Gln Ser Gln Good Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn G	480 Ile
Glu Pro Lys Ala Thr Thr Leu Leu Arg Ser Ile Leu Ile Leu His 500 Asn Thr Gly Tyr Val Phe Cys Val Ile Asp Val Asp Ile Tyr Ala 525 Ile Asn Val Pro Gly Ile Tyr Arg Ala Pro Asp Lys Leu Pro Lys 530 The Lys Pro Leu Pro Ile Ile Pro Ile Ile Gly Leu Lys Glu Pro 545 Ser Trp Gly Ile Ser Thr Ile Arg Tyr Phe Ala Lys Gln Thr Phe 565 Lys Asn Lys Ser Leu Thr Asn Pro Gly Val Asp Asn Pro Asn Leu 590 Glu Gly Val Val Pro Ser Asp Glu His Ile Ser Ser Gln Ser Gln 605 Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu 610 Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Thr Thr	
Asn Thr Gly Tyr Val Phe Cys Val Ile Asp Val Asp Ile Tyr Ala 525	
515	Val
530 535 540 Ile Lys Pro Leu Pro Ile Ile Pro Ile Ile Gly Leu Lys Glu Pro 545 Ser Trp Gly Ile Ser Thr Ile Arg Tyr Phe Ala Lys Gln Thr Phe 575 Lys Asn Lys Ser Leu Thr Asn Pro Gly Val Asp Asn Pro Asn Leu 580 Glu Gly Val Val Pro Ser Asp Glu His Ile Ser Ser Gln Ser Gln 605 Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu 610 Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Thr Thr Asn Gln Pro Thr Asn Gln Pro Thr	Lys
545 550 555 Ser Trp Gly Ile Ser Thr Ile Arg Tyr Phe Ala Lys Gln Thr Phe 575 Lys Asn Lys Ser Leu Thr Asn Pro Gly Val Asp Asn Pro Asn Leu 580 Glu Gly Val Val Pro Ser Asp Glu His Ile Ser Ser Gln Ser Gln 605 Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu 620 Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Val 635 Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr Asn Gln Pro Thr Thr	Trp
575 Lys Asn Lys Ser Leu Thr Asn Pro Gly Val Asp Asn Pro Asn Leu 580 Glu Gly Val Val Pro Ser Asp Glu His Ile Ser Ser Gln Ser Gln 605 Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu 610 Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Val 625 Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr Asn Gln Pro Thr Thr Asn Gln Pro Thr	Leu 560
Glu Gly Val Val Pro Ser Asp 595 Glu His Ile Ser Ser Gln Ser Gln 605 Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu 610 Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Val 625 Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr	Ile
Gln Leu Leu Ser Pro Leu Ala Thr Pro Phe Gln Val Ile His Leu 610	Ser
Gln Ser Thr Asn Gln Pro Ile Asn Gln Pro Thr Asn Gln Pro Val 625 Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr	Ile
625 630 635 Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr Asn Gln Pro Thr	Asn
	Asn 640
645 650 655	Asn
Gln Pro Thr Asn Gln Ser Thr Asn Gln Pro Thr Asn Gln Pro Asn 660 665 670	Asn
Gln Pro Thr Asn Gln Ser Thr Lys Gln Pro Thr Asn Gln Pro Val 675 680 685	Asn
Gln Ser Thr Asn Gln Pro Ile Asn Gln Ser Thr Lys Gln Pro Asn 690 695 700	Asn
Gln Pro Ile Asn Gln Ser Thr Lys Gln Pro Thr Asn Gln Pro Val 705 710 715	Asn 720
Gln Pro Asn Asn Gln Ser Thr Asn Gln Pro Thr Asn Gln Pro Ile 725 730 730	Asn
Gln Thr Thr Asn Gln Pro Asn Asn Gln Pro Thr Ser Gln Pro Thr 740 745 750	Asn
Gln Pro Val Asn Gln Pro Ile Asn Gln Ser Thr Asn Gln Thr Thr 755 760 765	Asn
Gln Ser Thr Asn Gln Pro Ile Asn Gln Ser Thr Lys Gln Pro Thr 770 775 780	Lys
Gln Pro Thr Asn Gln Pro Asn Asn Gln Thr Thr Asn Gln Ser Thr 785 790 795	Ser 800
Gln Pro Thr Lys Gln Pro Ile Ser Gln Pro Ile Asn Gln Pro Asn 805 810 815	Asn
Ile Met Gly Asp Lys Arg Gly Leu Lys Gly Ala Glu Thr Met Ser 820 825 830	Pro
Ala Pro Leu Phe Val Glu Val Asp Ile Leu Lys Asp Ser Leu Asp 835 840 845	
Asn Leu Glu Val Leu Tyr Gln Val Ser Val Asn Ala Ile Met Phe 850 855 860	

-continued

Arg Val Ala Arg Asn Met Ala Ser Asn Ile Ile Ile Lys Ser Val Lys 870 Val Gly Glu Asp Ile Leu Tyr Leu Asn Asp Arg Arg Leu Asp Leu Ile 885 890 Leu Glu Phe Thr Val Thr Ser Gln Gln Gly Phe His Met Arg Ile Tyr Asn Asn Asp Asp Arg Thr Glu Asn Gly Val Ile Gly Phe Leu Cys Ser 920 Phe Ile Val Ala Asp His Ile Pro Lys Trp Tyr Asn Pro Pro Asn Ser Arg Arg 945 <210> SEQ ID NO 9 <211> LENGTH: 816 <212> TYPE: DNA <213> ORGANISM: Babesia microti <400> SEQUENCE: 9 atgacagtaa caactatcgc attgactgtt tcaatcgtat catatataca tggttctcca 60 tcaaatggcc tctatgaatc taaccttttt tacacggaag gttatggcaa atatttgact 120 agtccgacta agataaagac aattgaattt ggaggttata aattcgagtt tgatgatgat 180 acattqcctq taacatctat aacaaaaatc qatqtaataa catatqatqa taaaccqatt 240 ttatttgaat ttatttcaga taaggatcgt ccatacagaa gattttacta ctatactttg 300 gatagtaaaa ctaataaatt atataattat gtcactgcag aaactggata taatgttgag 360 gattcgagtg gtctaaaata ctacactgaa ttaagtaaat cgggaataaa tgatgtttta 420 caagatttgg ataaaaacat tgatgaaagt aatatcgagc atttgaagac atcatatgta 480 acaaaaggat taaatattgc gattgaagtt tattcaaaca gagtcgttga acaaattaaa 540 togataaagg tagttactoo agttgaatta ttogattata aaactgaagt tocaattgag 600 totgtagato atgaatogog tgataattoa ttggoogaag tagaggagga tggaaaagot 660 gtacaagttg ggactcaacc tgtgtatgag gtaaatgatg gtgctcataa cccatctgca 720 caagtgttat cacagaataa tattattgag accttggatg ataaatctaa agttactcat 780 816 ttgagaaatg ctggcagtga gaaaattcgt gtttaa <210> SEQ ID NO 10 <211> LENGTH: 271 <212> TYPE: PRT <213> ORGANISM: Babesia microti <400> SEQUENCE: 10 Met Thr Val Thr Thr Ile Ala Leu Thr Val Ser Ile Val Ser Tyr Ile His Gly Ser Pro Ser Asn Gly Leu Tyr Glu Ser Asn Leu Phe Tyr Thr Glu Gly Tyr Gly Lys Tyr Leu Thr Ser Pro Thr Lys Ile Lys Thr Ile 40 Glu Phe Gly Gly Tyr Lys Phe Glu Phe Asp Asp Asp Thr Leu Pro Val Thr Ser Ile Thr Lys Ile Asp Val Ile Thr Tyr Asp Asp Lys Pro Ile 70 Leu Phe Glu Phe Ile Ser Asp Lys Asp Arg Pro Tyr Arg Arg Phe Tyr

				85					90					95	
Tyr	Tyr	Thr	Leu 100	Asp	Ser	Lys	Thr	Asn 105	Lys	Leu	Tyr	Asn	Tyr 110	Val	Thr
Ala	Glu	Thr 115	Gly	Tyr	Asn	Val	Glu 120	Asp	Ser	Ser	Gly	Leu 125	Lys	Tyr	Tyr
Thr	Glu 130	Leu	Ser	Lys	Ser	Gly 135	Ile	Asn	Asp	Val	Leu 140	Gln	Asp	Leu	Asp
Lys 145	Asn	Ile	Asp	Glu	Ser 150	Asn	Ile	Glu	His	Leu 155	ГÀз	Thr	Ser	Tyr	Val 160
Thr	Lys	Gly	Leu	Asn 165	Ile	Ala	Ile	Glu	Val 170	Tyr	Ser	Asn	Arg	Val 175	Val
Glu	Gln	Ile	Lys 180	Ser	Ile	Lys	Val	Val 185	Thr	Pro	Val	Glu	Leu 190	Phe	Asp
Tyr	ГÀа	Thr 195	Glu	Val	Pro	Ile	Glu 200	Ser	Val	Asp	His	Glu 205	Ser	Arg	Asp
Asn	Ser 210	Leu	Ala	Glu	Val	Glu 215	Glu	Asp	Gly	Lys	Ala 220	Val	Gln	Val	Gly
Thr 225	Gln	Pro	Val	Tyr	Glu 230	Val	Asn	Asp	Gly	Ala 235	His	Asn	Pro	Ser	Ala 240
Gln	Val	Leu	Ser	Gln 245	Asn	Asn	Ile	Ile	Glu 250	Thr	Leu	Asp	Asp	Lys 255	Ser
Lys	Val	Thr	His 260	Leu	Arg	Asn	Ala	Gly 265	Ser	Glu	ГАв	Ile	Arg 270	Val	

The invention claimed is:

1. A method for detecting antibodies specific for *Babesia microti* in a biological sample, comprising:

providing at least one *B. microti* antigenic polypeptide immobilized on a solid support, wherein the at least one antigenic polypeptide is selected from a polypeptide comprising an amino acid sequence with no more than 5 conservative amino acid substitutions relative to SEQ ID NO: 2, a polypeptide comprising an amino acid sequence with no more than 5 conservative amino acid substitutions relative to SEQ ID NO: 4 and a polypeptide comprising an amino acid sequence with no more than 5 conservative amino acid substitutions relative to SEQ ID NO: 6;

contacting the solid support with the biological sample under conditions sufficient to allow binding of any *B. microti*-specific antibodies present in the biological sample to the at least one *B. microti* antigenic polypeptide, thereby forming antigen-antibody complexes; 50 and

detecting the antigen-antibody complexes.

- 2. The method of claim 1, wherein detecting the antigenantibody complexes comprises:
 - contacting the antigen-antibody complexes with a secondary antibody conjugated to a label; and
 - detecting binding of the secondary antibody to the antigen-antibody complexes.
- 3. The method of claim 2, wherein the label comprises an enzyme and detecting binding of the secondary antibody to the antigen-antibody complexes comprises detecting activity of the enzyme.
- **4**. The method of claim **3**, wherein the enzyme is horse-radish peroxidase (HRP).
- **5**. The method of claim **2**, wherein the label comprises a fluorescent protein and detecting binding of the secondary antibody to the antigen-antibody complexes comprises detecting fluorescence.

- **6**. The method of claim **2**, wherein the secondary antibody comprises anti-human IgG, anti-human IgM, or both.
- 7. The method of claim 1, wherein the at least one antigenic polypeptide is selected from a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 6.
- **8**. The method of claim **1**, wherein the at least one antigenic polypeptide comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 6.
- 9. The method of claim 1, wherein the biological sample comprises blood or serum.
- 10. The method of claim 1, wherein the solid support comprises a multi-well plate, a membrane, a bead, a microsphere, a test tube, a test stick or a test strip.
- 11. The method of claim 1, wherein the solid support comprises a multi-well plate.
- 12. The method of claim 1, wherein the at least one antigenic polypeptide is selected from a polypeptide comprising an amino acid sequence with no more than 2 conservative amino acid substitutions relative to SEQ ID NO: 2, a polypeptide comprising an amino acid sequence with no more than 2 conservative amino acid substitutions relative to SEQ ID NO: 4 and a polypeptide comprising an amino acid sequence with no more than 2 conservative amino acid substitutions relative to SEQ ID NO: 6.
 - 13. A composition comprising a *Babesia microti* antigenic polypeptide immobilized on a solid support, wherein the amino acid sequence of the *B. microti* antigenic polypeptide consists of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6

46

- **14**. The composition of claim **13**, wherein the solid support comprises a multi-well plate, a membrane, a bead, a microsphere, a test tube, a test stick or a test strip.
- 15. The composition of claim 13, wherein the solid support comprises a multi-well plate.
- **16**. The composition of claim **13**, wherein the composition comprises the *B. microti* antigenic polypeptide consisting of SEQ ID NO: 2, the *B. microti* antigenic polypeptide consisting of SEQ ID NO: 4 and the *B. microti* antigenic polypeptide consisting of SEQ ID NO: 6 immobilized on a 10 solid support.

* * * * *